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ABSTRACT
Jung In Kim: Contributions to the Analyses of Recurrent Events and Competing Risk
(Under the direction of Jason Fine)
There is a growing interest in the analysis of recurrent events data. Recurrent events are
frequently considered as an outcome when a subject could possibly experience more than
one event over follow-up period. Thus, It is important to consider previous events history
to explore the relationship between the effects of covariates and the correlated failure times.
We extend the Cox-type model with time-varying effect depending on the number and the
gap time between previous events to enhance both model fit and prediction. Parameter
estimation and statistical inference can be achieved via the partial likelihood. A statistical
test procedure is provided to assess the existence of the triggering effects. We demonstrate
our approach via comprehensive simulation studies and chronic pseudomonas infections in
young cystic fibrosis patients data. Significantly, our model provides better predictions than
the existing models.
When some patients do not adhere to their assigned treatments in a randomized trial,
the standard intention-to-treat analysis may not properly estimate the effect of treatment on
the outcome. Also, considering only received treatment without accounting for unmeasured
confounders could be biased. Therefore, it is challenging to obtain the true treatment effect,
which can be observed when all subjects comply their assigned regime. Instrumental variable
methods help us to consistently estimate the average causal effect of an exposure on some
outcome of interest even in the presence of latent confounding. We apply Abadie’s weighting
scheme to estimate corresponding local average response functions in survival analysis. The
method is demonstrated by simulation studies and the colorectal cancer screening data,
designed and sponsored by the National Cancer Institute.
iii
Competing risks also occur when subjects can experience one or more events which
compete with the outcome of interest. In these cases, the competing risk inhibits to observe
the event of interest or modifies the chance that this event occurs. We extend existing
parametric approaches to estimate the cumulative incidence function for considering both
left truncation and interval in competing risks settings. This parametric method is applied
to data from the study of osteoporotic fractures to bone mineral density testing interval with
age as time scale.
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CHAPTER 1: LITERATURE REVIEW
1.1 Survival Analysis
1.1.1 Single Failure Time Data
The Cox proportional hazards regression model [1] is the most commonly applied for
analyzing censored survival data. The model quantifies the hazard rate λ(t) = limh↓0 1hP (T ≤
t+ h|T > t), where T is the survival time of an individual, with covariate vector Z such as
λ(t) = λ0(t) exp(β
′Z), (1.1.1)
where t ≥ 0, λ0(t) is an unspecified baseline hazard function and β is a p-vector of unknown
regression coefficients. Let λ(t|z1) and λ(t|z2) be the hazard functions given covariate vectors
z1 and z2 respectively. Define the hazard ratio of z1 with respect to z2 as r(t|z1, z2) = λ(t|z1)λ(t|z2) =
exp(β′z1 − β′z2), which does not depend on time t. The hazard ratio is interpreted as the
instantaneous failure at time t of a subject with covariate vector z1 is r(t|z1, z2) times as
likely as a subject with covariate vector z2. This ratio is of primary interest in survival
analysis.
Let Ti be the failure (survival) time, Ci denote the potential censoring time, Xi =
min(Ti, Ci) denote the observed time for the subject i, and δi = I(Ti ≤ Ci), where I(·)
is the indicator function. Suppose that there are n independent subjects, i.e., i = 1, . . . , n.
The following partial likelihood function is considered to estimate β [1, 2].
PL(β) =
n∏
i=1
{
exp(β′Zi)∑
k∈Ri exp(β
′Zk)
}δi
, (1.1.2)
1
where the risk set Ri = {k : Xk ≥ ti}, i.e., all individuals who have not died or been censored
yet by ti. Then, β is estimated by βˆ maximizing (1.1.2).
1.1.2 Recurrent Failure Time Data
Repeated failure events are frequently considered in a longitudinal study when subjects
could possibly experience more than one event during the study period. The failures can be
repeated by the same type of event or caused by different natures. In this thesis, Chapter 2
and 3 are related to the former case and Chapter 4 covers the latter case.
To explore the relationship between the effects of covariates and the correlated failure
times, the Cox proportional hazards model [1] was extended to a multivariate counting
process model allowing for time varying covariates with assuming independent increments
[3]. To formulate in a counting process form, the data for the subject i, (Xi, δi) is re-expressed
as {Ni(t), Yi(t)}. The right continuous N(t) is referred to as the counting process defined
by Ni(t) = N
∗
i (t ∧ Ci), where N∗i (t) is the number of events that occur during the interval
[0, t] and Ci is the censoring time for subject i. The left continuous Y (t) is referred to as the
at-risk process given by Yi(t) = I(Xi ≥ t), indicating the ith subject is under observation by
the value t. Thus, the β also can be estimated by maximizing the logarithm of the following
partial likelihood
C(β) =
n∑
i=1
∫ τ
0
β′Zi(s)dNi(s)−
∫ τ
0
log
{
n∑
i=1
Yi(s) exp{β′Zi(s)}
}
dN¯(s), (1.1.3)
where τ is the end of study time and N¯ =
∑n
i=1Ni. The estimator βˆ is defined as the
solution to the score equation given by
U(t; β) =
n∑
i=1
∫ t
0
Zi(s)dNi(s)−
∫ t
0
∑n
i=1 Yi(s)Zi(s) exp{β′Zi(s)}∑n
i=1 Yi(s) exp{β′Zi(s)}
dN¯(s). (1.1.4)
From the score function (1.1.4), the following form can be derived in terms of a local mar-
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tingale:
U(t; β) =
n∑
i=1
∫ t
0
Zi(s)dMi(s)−
∫ t
0
∑n
i=1 Yi(s)Zi(s) exp{β′Zi(s)}∑n
i=1 Yi(s) exp{β′Zi(s)}
dM¯(s), (1.1.5)
where M¯ =
∑n
i=1Mi, and Mi(t) = Ni(t) −
∫ t
0
λi(s)ds. There are additional definitions
such as: S(r)(t; β) = n−1
∑n
j=1 Zj(t)
⊗rYj(t) exp{β′Zj(t)}, r = 0, 1, 2, E(t; β) = S(1)(t;β)S(0)(t;β) , and
V (t; β) = S
(2)(t;β)
S(0)(t;β)
− E(t; β)⊗2. Also, their corresponding limiting values were defined as s(r)
for r = 0, 1, 2, e = s(1)/s(0), and v = s(2)/s(0) − e⊗2, respectively. Under some regularity
conditions in [3], the estimated βˆ has consistency and asymptotic normality with mean β0
and covariance matrix Σ−1, where Σ =
∫ τ
0
v(t, β)s(0)(t, β)λ0(t)dt. The Σ is estimated by the
partial likelihood observed information evaluating at β = βˆ. The estimator of the cumulative
baseline intensity function Λ0(t) =
∫ t
0
λ0(s)ds is given by
Λˆ0(t; βˆ) =
∫ t
0
∑n
i=1 dNi∑n
i=1 Yi(s) exp{βˆ′Zi(s)}
. (1.1.6)
Prentice et al. [4] proposed two arbitrary baseline intensity functions. One is a function
of time from the beginning of the study and the other one is a function of time from the
previous failure time. Let Z(t) = {Z1(t), . . . , Zp(t)} denote p covariate processes at time t,
and N(t) be a counting process, i.e., the random number of failures prior up to time t. Thus,
the corresponding intensity functions are following:
λCP{t|N(t)} = λ0m(t) exp{β′mZ(t)},
λGT{t|N(t)} = λ0m(t− tN(t)) exp{β′mZ(t)},
(1.1.7)
where λ0m(·) ≥ 0, m = N(t) + 1, i.e., m = 1, 2, . . . and βm is a stratum-specific regression
coefficients vector. The corresponding partial likelihoods can be written as
PLCP (β) =
∏
m≥1
dm∏
i=1
exp{β′mZmi(tmi)}∑
k∈R(tmi,m) exp{β′mZmk(tmi)}
, (1.1.8)
where tmi denotes a failure time in stratum m for subject i and dm is a total number of
failures in stratum m, and
PLGT (β) =
∏
m≥1
dm∏
i=1
exp{β′mZmi(tmi)}∑
k∈R(umi,m) exp{β′mZmk(lk + umi)}
, (1.1.9)
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where lk is the last failure time of subject k prior to the entry into stratum m and umi implies
that subject i fails in stratum m with a gap time umi at time tmi. Kelly et al. [5] suggested
to use the gap time model to analyze recurrent event data when within-subject events are
independent because it determines whether the treatment is effective for the mth event since
the time from the previous event.
Wei et al. [6] suggested marginal distributions for the multivariate failure times. Each of
the distributions is also based on the Cox proportional hazards model [1]. There is no specific
constraint for dependence among the different failure times within each subject. Similar to
Prentice et al. [4] each event or event type is modeled as a separate stratum. Within each
strata, the marginal data is used, that is, all information is ignored except the given event
type. As a result, each patient normally appears in all of the strata, barring deletion due to
missing values [7]. For the mth type of failure, m = 1, . . . ,M , of the ith subject, the hazard
function is given by
λm(t) = λ0m(t) exp{β′mZm(t)}, (1.1.10)
where βm is the failure-specific regression coefficients vector. The corresponding mth failure-
specific partial likelihood is
PLm(β) =
n∏
i=1
[
exp{β′mZmi(tmi)}∑
k∈R(tmi) exp{β′mZmk(tmi)}
]δmi
. (1.1.11)
Similarly, βm is estimated by solving the equation ∂ logPLm(β)/∂β = 0. The estimated
(βˆ′1, . . . , βˆ
′
M)
′ is approximately normal with mean (β′1, . . . , β
′
M) and covariance matrix ΣM×M
with σkl(βk, βl) = A
−1
k (βk)E[wk1(βk)wl1(βl)
′]A−1l (βl) for k, l = 1, . . . ,M , where
Ak(βk) = E
[∫ τ
0
{Zk(t)− ek(t; βk)}⊗2Yk(t) exp{β′kZk(t)}dΛ0k(t)
]
,
wki(βk) =
∫ τ
0
{Zki(t)− ek(t; βk)}dMki(t),
Mki(t) = Nki(t)−
∫ t
0
Yki(s)λki(s)ds,
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S
(r)
k (t; β) = n
−1
n∑
i=1
Z⊗rki Yki(t) exp{β′Zki(t)}, for r = 0, 1, 2,
Ek(t; β) = S
(1)
k (t; β)/S
(0)
k (t; β), and ek(t; β) be the corresponding limit. This marginal
method is a useful tool for making inferences on the population average effect of covari-
ates on failure times. However, it cannot provide insights into the interrelationship among
failure times [7, 8]. Also, Kelly et al. [5] suggested this method is more appropriate to
data where there are different types of events from a same person than to recurrent event
data. These two aforementioned approaches by Prentice et al. [4] and by Wei et al. [6] use
stratified proportional hazards model with a separate stratum depending on the number of
previous events. Thus, those methods could be proper for only handling a small number of
recurrent events. Since there is a case with some strata that does not have enough subjects
or a case where there are too many number of parameters to be estimated, those models
might not get stable hazard estimates.
The existing Cox type hazards functions for analyzing recurrent event data have been
reviewed. These methods are assumed that the underlying counting process is a time variant
Poisson process. Lin et al. [9] suggested a robust procedure for treating all recurrent events
within a subject as a single counting process without assumption related to the poisson
process. By denoting E[dN(t)|Z(t)] = dµ(t),
dµ(t) = exp{β′0Z(t)}dµ0(t), or (1.1.12)
µ(t) =
∫ t
0
exp{β′0Z(s)}dµ0(s), (1.1.13)
where µ0(·) is an unknown function. Model (1.1.12) is referred to as the proportional rates
(means) model. Model (1.1.1) implies model (1.1.12) with dµ0(t) = λ0(t), but not in reverse.
The corresponding inferences are similar to arguments in [3]. [9] imposed the following
regularity conditions, for i = 1, . . . , n:
(i) {Ni(·), Yi(·), Zi(·)} are independent and identically distributed.
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(ii) Pr(Yi(τ) = 1) > 0, where τ is a predetermined study end time.
(iii) Ni(τ) are bounded.
(iv) Zi(·) are bounded total variations, i.e., |Zij(0)| +
∫ τ
0
|dZij(t)| ≤ K for all j = 1, . . . , p,
where Zij is the jth element of Zi and K is a constant.
(v) A ≡ E[∫ τ
0
{Z(t)− E(β0, t)}⊗2Y (t) exp{β′0Z(t)}dµ0(t)] is positive definite.
Then, n−1/2U(t; β0), 0 ≤ t ≤ τ converges weakly to a continuous zero mean Gaussian process
with covariance matrix
Σ(s, t) = E
[∫ s
0
{Z1(u)− E(u; β0)}dM1(u)
∫ t
0
{Z1(v)− E(v; β0)}dM1(v)
]
,
0 ≤ s, t ≤ τ between time points s and t. Also, they proved that βˆ has asymptotic normality
with mean β0 and covariance matrix Γ = A
−1ΣA−1, where Σ = Σ(τ, τ). The covariance
matrix Γ can be consistently estimated with these subsequent quantities:
µˆ0(t) =
∫ t
0
dN¯(s)
nS0(s; βˆ)
,
Aˆ = −n−1
n∑
i=1
∫ τ
0
{Zi(s)− E(s; βˆ)}⊗2Yi(s) exp{βˆ′Zi(s)}dµˆ0(s),
Σˆ = n−1
n∑
i=1
∫ τ
0
{Zi(u)− E(u; βˆ)}dMˆi(u)
∫ τ
0
{Zi(v)− E(v; βˆ)}dMˆi(v),
Mˆi(t) = Ni(t)−
∫ t
0
Yi(s) exp{βˆ′Zi(s)}dµˆ0(s).
Additionally, a random weight function Q(t; βˆ) is incorporated into U(τ, β), then the follow-
ing weighted estimating functions for β0 are obtained:
UQ(τ ; β) =
n∑
i=1
∫ τ
0
Q(s; βˆ){Zi(s)− E(s; β)}dNi(s). (1.1.14)
They assumed that the weight function is non-negative, bounded and monotone in t, and
converges almost surely to a continuous deterministic function q(t) in t ∈ [0, τ ]. By solv-
ing UQ(τ ; β) = 0, β0 can be estimated by βˆQ. Also, they showed that n
1/2(βˆQ − β0) is
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asymptotically zero mean normal with covariance matrix A−1Q ΣQA
−1
Q , where
AQ = E
[∫ τ
0
q(t){Z1(t)− E(t; β0)}⊗2Y1(t) exp{β′0Z1(t)}dµ0(t)
]
,
ΣQ = E
[∫ τ
0
q(u){Zi(u)− E(u; β0)}dM1(u)
∫ τ
0
q(v){Zi(v)− E(v; β0)}dM1(v)
]
.
Note that the weight function Q(t; βˆ) does not relate to β.
1.2 Instrumental Variable Methods
Instrumental variable (IV) analysis is commonly applied to estimating the exposure effect
for the data with unmeasured confounders. For example, in a randomized trial, subjects often
do not comply with their assigned treatment protocols. Hence, a subject’s actual treatment
may differ from his or her assigned treatment, i.e., compliance might not be random. To
estimate the true causal effect of an exposure on an outcome, we may use IV. The valid IV
should have the following properties such as i) affect treatment (endogenous covariate) or
be associated with treatment by sharing a common cause; ii) be a factor that is as good as
randomly assigned and iii) related to the outcome only through the treatment [10]. Even
though recurrent failure event time data are frequently obtained in many randomized clinical
trials or observational studies, there is only a handful of studies that analyze it by dealing
with non-compliance problem. Thus, existing IV methods mostly for time-to-event data,
i.e., univariate failure time data, are reviewed.
An intent-to-treat analysis is more commonly used without considering the presence of
non-compliance. For example, if Z is denoted as a randomization indicator, i.e., Z = 1 for
individuals randomized to receive an active treatment and Z = 0 otherwise, then we can
model the intent-to-treat treatment effect as λ(t|Z) = λ0(t) exp(β0Z). The parameter β0
is not to measure the true causal effect of treatment, but rather a mixture of the effect on
the compliers with the absence of effect on the non-compliers due to their non-compliance.
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Thus, the measure of treatment effect under intent-to-treat analysis would diminish as non-
compliance increased.
Several IV methods for right-censored event time outcome data have been proposed. The
following models could plausibly be used: the rank preserving structural failure time model
(RPSFTM) [11], the marginal structural Cox proportional hazards model [12–14] and the
method of inverse probability of censoring weighted log-rank tests [15].
The causal parameter of interest will often be a function of the survival differences that
would have been observed, contrary to fact that all subjects remained on protocol. Robins
and Tsiatis [11] proposed the RPSFTM using a class of rank estimators to estimate the
survival differences with correcting non-compliance issue. This model is a strong version
of the accelerated failure time (AFT) model with time-dependent covariates proposed by
[16]. The ranking preserving implies that given any two subjects i and j, if subject i fails
before subject j when both followed a particular treatment regime, then subject i would
fail before subject j when both followed any other regime. Let Ui denote the survival
time of the subject i when he or she is never to receive treatment, i.e., Di(t) = 0 for
all t. In the absence of censoring, the observable random variables are {Ti, Hi(Ti), Zi}
are independently and identically distributed, where Ti is the observed survival time of
ith subject, Hi(Ti) = (Di(s); 0 < s ≤ Ti) is the observed treatment history, and Zi is
a randomization group indicator. Simply, the RPSFTM assumes that the baseline latent
lifetime variable, Ui, is related to these observable random variables by the relationship
Ui =
∫ Ti
0
exp{β0Di(s)}ds, (1.2.1)
where β0 is an unknown parameter. More generally, the RPSFTM links the variable Ui to
{Ti, Hi(Ti)} by assuming Ui = ψ(Ti, Hi(Ti), β0), where β0 ∈ Rp is an unknown parameter
and ψ(·) is a known smooth function. The following properties are satisfied by:
(i) smoothness: ψ1(t, h(t), β), ψ3,p(t, h(t), β), and ψ13,p(t, h(t), β) are continuous for all β
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and almost all t, where ψ1(t, h(t), β) ≡ ∂ψ(t, h(t), β)/∂t, ψ3,p(t, h(t), β) ≡ ∂ψ(t, h(t), β)/∂βp,
ψ13,p(t, h(t), β) ≡ ∂ψ1(t, h(t), β)/∂βp.
(ii) Monotonicity: ψ(t, h(t), β) > ψ(s, h(s), β) if t > s.
(iii) Identity: ψ(t, h(t), 0) = t
(iv) Independence and Identification: There exists a unique β0 such that U(β0) |= Z,
where U(β) = ψ(T,H(T ), β).
Thus, β0 can be considered as the true value of β with a casual interpretation. Standard
nonparametric methods can be applied to test the null hypothesis β0 = 0.
In the marginal structural Cox proportional hazards model [12–14], the Cox proportional
hazards model [1, 16], which is a standard semi-parametric method, was adopted rather
than the AFT model. The parameter of interest in the marginal structural Cox proportional
hazard model is the counterfactual hazard ratio rather than survival time itself. Loeys and
Goetghebeur [14] proposed the Complier PROPortional Hazards Effect of Treatment (C-
PROPHET). Suppose that n independent individuals were randomized over experimental
exposure (Zi = 1) or control (Zi = 0). Either (Di1, Ti1) or (Di0, Ti0) is observed, where
Di1 = 1 denotes that subject i received the treatment and Ti1 is the corresponding right
censored survival time when Zi = 1. The following assumptions are required:
(i) (Di1, Ti1, Di0, Ti0, Zi) are independent and identically distributed random variables, im-
plying that potential outcomes for each subject are unrelated to the treatment or out-
come experienced by other individuals.
(ii) randomization: (Di0, Ti0, Di1, Ti1) |= Zi.
(iii) No access to treatment on the control arm. That is, Di0 = 0 for all subjects, and Ti0
represents the treatment-free survival time outcome, when randomized to control.
(iv) exclusion restriction: Pr(Ti1 > t|Di1 = 0) = Pr(Ti0 > t|Di1 = 0).
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Under the randomized treatment assignment Zi, the treatment actually received can be
written as Di = (1 − Zi)Di0 + ZiDi1. The observation time is defined as Xi = min(Ti, Ci),
with Ti = (1−Zi)Ti0 +ZiTi1, the observed survival time, possibly censored at time Ci. The
corresponding censoring indicator is denoted by δi = I(Ti ≤ Ci). Additionally, they assumed
(v) independent censoring: (Ti, Di, Zi) |= Ci or weaker assumption that censoring is non-
informative for the control arm as a whole, while in the experimental arm, censoring is
a non-informative conditional on treatment exposure.
To estimate C-PROPHET, Pr(Ti0 > t|Di1 = 1) = Pr(Ti > t|Zi = 0, Di1 = 1) and Pr(Ti1 >
t|Di1 = 1) = Pr(Ti > t|Zi = 1, Di1 = 1) are compared by using a proportional hazards
model. That is, C-PROPHET implies that the proportional hazards of treatment in the
subpopulation that has received the treatment. Within this subgroup D1i = 1, the two
hazard rate functions have a relationship as follows:
λ(t|Zi = 1, Di1 = 1) = λ(t|Zi = 0, Di1 = 1) exp(ψ0), (1.2.2)
where exp(ψ0) denotes the causal proportional hazards effect within the treatable subpop-
ulation. However, the estimator proposed by Loeys and Goetghebeur [14] is limited to the
setting of all-or-nothing compliance exposure. To overcome this limitation, Loeys et al. [17]
extended it to more general causal proportional hazards models that allow for time-constant
discrete and continuous exposure levels. Suppose that there are n independent subjects are
randomly assigned to treatment (Zi = 1) or control (Zi = 0). Let Xi denote a covariate
vector measured prior to randomization. Subjects randomized to treatment arm may receive
control therapy, but subjects on the control arm have no access to treatment and thus ad-
here to their assigned treatment. Let Ui denote that subject i’s potential exposure to the
treatment if the subject were randomized to treatment and Di = ZiUi indicated the ob-
served exposure for all subjects. That is, Ui cannot be observed in control arm but Di = 0.
Under non-informative censoring, Xi = min(Ti, Ci), and corresponding censoring indicator
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δi = I(Ti ≤ Ci) are defined. To contrast the observed hazard in the treated group versus
the unobserved subpopulation-specific hazards in the control group, the following causal
proportional hazards model is considered:
λ(t|Zi = 1, Ui = u,Xi = xi) = λ(t|Zi = 0, Ui = u,Xi = xi) exp(ψ0u), (1.2.3)
where ψ0 is the unknown parameter of interest. The fundamental problem of estimating ψ0
is that all subjects in the control group (Zi = 0) have latent Ui. Randomization is the key
for the estimation procedure. The Eq.(1.2.3) is re-written in terms of survival distributions
such as
S(t|Zi = 1, Ui = u,Xi = xi) = S(t|Zi = 0, Ui = u,Xi = xi)exp(ψ0u). (1.2.4)
The survival probability in the control group are defined as a mixture of unobserved compliance-
specific probabilities given by
S(t|Zi = 0, Xi = xi) =
∑
u
S(t|Zi = 0, Ui = u,Xi = xi)Pr(Ui = u|Zi = 0, Xi = xi),
where Ui is discrete. Also, if Eq.(1.2.4) holds, then S(t|Zi = 0, Xi = xi) can be expressed as∑
u S(t|Zi = 1, Ui = u,Xi = xi)exp(−ψ0u)Pr(Ui = u|Zi = 1, Xi = xi) since Pr(Ui = u|Zi =
0, Xi = xi) = Pr(Ui = u|Zi = 1, Xi = xi) by definition of Ui and randomization. They
defined Sˆ1→0(t|Xi;ψ) as∑
u
Sˆ(t|Zi = 1, Ui = u,Xi = xi)exp(−ψu)Pˆ r(Ui = u|Zi = 1, Xi = xi).
The unknown parameter ψ0 is estimated by the value of ψ that minimizes the distance
between the Sˆ1→0(t|Xi;ψ) and the fitted treatment-free survival distribution in the control
arm conditional on Xi.
Robins and Finkelstein [15] proposed the inverse probability of censoring weighted (IPCW)
log-rank test for estimating the effect of treatment with non-compliance and a informative
censoring scheme. They assumed that there is no unmeasured confounders of censoring, that
is, the cause-specific intensity rate of censoring time λC(t), where Ci = t, does not depend on
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the possibly unobserved failure time Ti conditional on the assigned treatment Zi and recorded
historyHi(t) of all associated time variant covariatesXi(t), whereHi(t) = {Hi(s); 0 ≤ s ≤ t}.
This assumption can be expressed as λC(t|H(t), Z, T, T > t) = λC(t|H(t), Z, T > t) which
is different from the usual independent censoring assumption λT (t|Z,C ≥ t) = λT (t|Z),
where λT (t|Z,C ≥ t) denotes the cause-specific hazard of failure time Ti = t. Under the
assumption, the following model is considered
λC(t|H(t), Z, T > t) = λ0Z(t) exp{β′ZH(t)}. (1.2.5)
Since both the baseline hazards λ0Z(t) and βZ may depend on the treatment arm, this model
(1.2.5) can be separated by treatment-arm-specific models for censoring and then they are
fit to data from the two arms separately. Let X = min(T,C), Y (t) = I(X ≥ t) be the
at-risk indicator, and let δ = I(T ≤ C) be the censoring indicator. A consistent estimate of
the conditional probability that a subject i is uncensored through time t given (H(T ), Z, T )
is provided by the following time-dependent extension of the Kaplan-Meier (K-M) product
limit estimator for censoring:
KˆHi (t) =
∏
{j:Xj<t,δj=0,Zj=Zi}
[1− λˆZi(Xj) exp{βZiHi(Xj)}], (1.2.6)
where
λˆZ(Xj) =
1− δj∑n
i=1 Yi(Xj) exp{βZHi(Xj)}I(Zi = Z)
is the baseline hazard estimator for censoring λ0Z in arm Z. Let Kˆ
0
i (t) be the usual treatment-
arm-specific Kaplan-Meier estimator of the probability of being uncensored by time t in
treatment arm Zi, then the subject specific weight is defined Wˆi(t) = Kˆ
0
i (t)/Kˆ
H
i (t) so that
Wˆi(t) will be converged to one for all t if and only if there is no dependent censoring within
each treatment arm. Thus, IPCW K-M estimate of the treatment arm specific marginal
probability of remaining alive through time t is
SˆT (t|z) =
∏
{i:Xi<t}
1− δiWˆi(Xi)I(Zi = z)∑n
k=1 Yk(Xi)Wˆk(Xi)I(Zk = z)
. (1.2.7)
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Yu et al. [18] extended semiparametric linear transformation models that include the
proportional hazards model that was considered by Cuzick et al. [19] to estimate the dis-
tribution of survival times in the treatment and control groups, conditionally not only on
observed covariates, but on the latent compliance type. Under the two-arm randomized
trials with all-or-nothing compliance and time-to-event outcomes, let Xi be a p-dimensional
covariate vector, and let Z = (Z1, . . . , Zn) denote the n-vector of treatment assignments with
0 < Pr(Zi = 1) < 1, for i = 1, . . . , n. For all possible assignment vectors z = (z1, . . . , zn) ∈
{0, 1}n, let Diz = 1 denote that a subject i received the treatment under the assignment z
and let Tiz and Ciz similarly denote the potential event time and potential right censoring
time for subject i under assignment z, respectively. Let Ui = k denote subject i's latent
class membership: Ui equals 1 if i is an always-taker (Di0 = Di1 = 1), 2 if i is a complier
(Di0 = 0; Di1 = 1), 3 if i is a never-taker (Di0 = Di1 = 0) and 4 if i is a defier (Di0 = 1;
Di1 = 0). The following assumptions are required:
(i) stable unit treatment value assumption: For any assignments z and z′, if zi = z′i,
then Diz = Diz′ , Tiz = Tiz′ and Ciz = Ciz′ for i = 1, . . . , n. Thus, Diz ≡ Dizi ≡ Diz,
where z = 0 if zi = 0, and z = 1 otherwise; similarly, Tiz ≡ Tizi ≡ Tiz and Ciz ≡ Cizi ≡
Ciz.
(ii) random sampling: (Diz, Tiz, Ciz, Xi, Zi), i = 1, . . . , n, are independent and identically
distributed from the distribution of a random vector (Dz, Tz, Cz, X, Z).
(iii) random assignment conditional on covariates: D0, T0, C0, D1, T1, C1 |= Z|X.
(iv) conditional non-null compliance class: Pr(U = 2|X = x) > 0.
(v) conditional monotonicity: Pr(D1 ≥ D0|X = x) = 1.
(vi) exclusion restriction: For k = 1, 3 and for all t, Pr(T0 ≤ t|U = k,X = x) = Pr(T1 ≤
t|U = k,X = x).
They considered three estimands such as the (conditional) complier average causal effect
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(CACE), the time t effect on the (conditional) complier survival probability (CESP), and
the (conditional) complier quantile causal effect (CQCE):
CACE(x) = E[T1 − T0|U = 2, X = x],
CESP (t;x) = Pr(T1 > t|U = 2, X = x)− Pr(T0 > t|U = 2, X = x),
CQCE(q;x) = sup{t : Pr(T1 ≤ t|U = 2, X = x) ≤ q}−sup{t : Pr(T0 ≤ t|U = 2, X = x) ≤ q}.
The causal linear transformation model for the potential event time distributions cannot be
directly used for estimation by using the observed data. Since only Ti = ZiTi1 + (1Zi)Ti0 is
observed. Thus, they proposed the following model with only using the parameters that are
related to the Ti:
log{H(Ti)} = −
3∑
k=1
(β0k + βkZi + η
′
kXi)I(Ui = k) + i, (1.2.8)
where H(·) is an unspecified continuously differentiable increasing function with H(0) = 0,
the random errors i are independent, identically distributed, and independent of Ui, Xi, Zi.
Additionally they assumed
(vii) (independent censoring of potential outcomes) For z = 0, 1, Cz |= z, Cz |=
U |X.
Thus, the observed data are (Yi,∆i, Xi, Di, Zi) with realized values (yi, δi, xi, di, zi) for i =
1, . . . , n. The log likelihood of the observed data is a mixture of distributions depending
on the compliance type probabilities pik = Pr(Ui = k|Xi = xi) since compliance class
cannot be fully observed. The pik can be calculated with the multinomial logit model with
log{pik(θ)/pi2(θ)} = θ′kxi, for k = 1, 3, and θ = (θ′1, θ′3)′. The corresponding likelihood
function of (yi, δi, xi, di, zi) for i = 1, . . . , n is given by
n∏
i=1
{(pi1gi1 + pi2gi2)I(di = zi = 1) + pi3gi3I(di = 0, zi = 1) + pi1gi1I(di = 1, zi = 0)
+ (pi2gi2 + pi3gi3)I(di = zi = 0)}λ1−δiC|X,Z(yi|xi, zi)SC|X,Z(yi|xi, zi)fX,Z(xi, zi), (1.2.9)
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where
gik =
{
λ[logH(yi) + β0k + βkzi + η
′
kxi]
h(yi)
H(yi)
}δi
exp {Λ[logH(yi) + β0k + βkzi + η′kxi]} ,
λC|X,Z and SC|X,Z are the conditional hazard and survivor functions of C given X,Z and
fX,Z is the density of X,Z. Since the distributions of the censoring time and covariates do
not depend on the parameters of interest, the likelihood (1.2.9) can be simplified as∏
di=zi=1
(pi1gi1 + pi2gi2)
∏
di=0,zi=1
pi3gi3
∏
di=1,zi=0
pi1gi1
∏
di=zi=0
(pi2gi2 + pi3gi3). (1.2.10)
The maximum likelihood estimator (MLE) can be obtained by maximizing the likelihood
(1.2.10) with respect to (θ, β01, β2, β03, η1, η2, η3, h1, . . . , hnu) subject to the constraints in
which h1, . . . , hnu are non-negative. They also showed that the MLE is consistent and has
asymptotic normality under the regularity conditions.
1.3 Competing Risks Analysis
So far, we have considered that there is only one event type of interest. However, in
many contexts it is likely that we can have several different types of failure. The occurrence
of one type of failure may prevent us from observing the other types of failures. The causes
of failure compete to occur or to be observed so it is referred to as competing risks. We
restrict ourselves to competing risk events where the follow-up duration of a patient ends at
the onset of the first event, and do not focus on multiple or recurrent events occurring in
a patient. For example, in cardiovascular studies, deaths from other causes are considered
as competing risks. There are two different ways to deal with competing risks setting such
as a latent failure time formulation and an approach of bivariate random variables with the
event time and the type of event. The former has the identifiability problem so the latter is
commonly used in modern competing risks analyses.
Specifically, one possible access for characterizing competing risks data is the latent failure
time. Let T˜j is the latent time variable due to cause j for j = 1, . . . , nJ , i.e, nJ is the number
15
of failure types. We observe T = min(T˜1, . . . , T˜J) in the absence of censoring. Functions
corresponding to the latent failure times are called marginal. The marginal hazard function
is defined as
λ˜j(t) = lim
h↓0
1
h
P (t ≤ T˜j < t+ h|T˜j > t). (1.3.1)
Also, the marginal survival function is S˜j(t) = P (T˜j > t) = exp{−Λ˜j(t)}, where Λ˜j(t) =∫ t
0
λ˜(s)ds. Note that the marginal functions for cause j do not consider other causes which
may not be practically relevant. The marginal functions are only estimable when T˜1 |= T˜2
|= . . . |= T˜J . However, this assumption is not verifiable [20].
In addition to the marginal functions, we can consider a bivariate random variable (T, J),
where T is a random variable for the event time and J is a random variable for the event
type. Thus, it leads to crude functions such as cause-specific hazard functions [21] and cu-
mulative incidence functions (subdistribution functions). The corresponding analysis can be
performed without identifiability problems and all measures can be estimated from observ-
able data. The cause-specific hazard for failure type j is given by
λ∗j(t) = lim
h↓0
1
h
P (t ≤ T < t+ h, J = j|T > t) (1.3.2)
for j = 1, . . . , J , and is interpreted as cause j failure hazard at time t, among subjects alive at
time t with acknowledging the existence of other causes by treating failures from other causes
as censored. Even though the cause-specific hazard function has a clear interpretation, the
corresponding function S∗j (t) = exp{−Λ∗j(t)}, where Λ∗j(t) =
∫ t
0
λ∗j(s)ds, does not. It implies
that when cause j is the only cause of failure then S∗j (t) would be equal to the survival
function. Another commonly used crude function is the cumulative incidence function (CIF)
defined as
Fj(t) = P (T ≤ t, J = j). (1.3.3)
It means the probability of observing the event of interest from cause j, acknowledging
that the subject may experience the event due to other causes first. It is not the same
quantity with P (T˜j < t), because T˜j cannot be observed when T˜k < T˜j, k 6= j. The name
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subdistribution function is driven by the fact that Fj(t) does not converge to one as t is going
to infinity. It represents the overall probability of the type j event such that
lim
t→∞
Fj(t) = P (J = j),
so it is not a proper probability distribution. Corresponding subsurvival function is Qj(t) =
P (T > t, J = j) and Qj(t) + Fj(t) = P (J = j) by the law of total probability. These CIF
and subsurvival function are estimable without assuming independence between the causes
of the failure. The CIF can be expressed in terms of the cause-specific hazards:
Fj(t) =
∫ t
0
S(u)λ∗j(u)du =
∫ t
0
exp{−Λ(u)}λ∗j(u)du (1.3.4)
=
∫ t
0
exp
{
−
J∑
j=1
∫ u
0
λ∗j(v)dv
}
λ∗j(u)du,
where S(t) is the overall survival function, S(t) = 1−∑Jj=1 Fj(t). This is often used for the
estimation of Fj(t). We can also define a cause-specific density at time t, say
fj(t) = lim
h↓0
1
h
P (t ≤ Ti < t+ h, J = j) = λ∗j(t)S(t). (1.3.5)
By the law of total probability, we have λ(t) =
∑J
j=1 λ
∗
j(t), because failure must be due to
one of the J causes, and similarly F (t) =
∑J
j=1 Fj(t) and f(t) =
∑J
j=1 fj(t).
Various nonparametric and semiparametric methods have been developed for modeling
the cumulative incidence function Fj(t). A subdistribution hazard function is considered
directly from the cumulative incidence function for cause j by Gray [22] in order to compare
the cumulative incidence of a particular type of failure amongst K different groups. The
corresponding function is defined by
λj(t) =
dFj(t)
{1− Fj(t)} (1.3.6)
= lim
h↓0
1
h
P{t ≤ Ti < t+ h, J = j|T ≥ t or (T ≤ t and J 6= j)}.
The conditional expression includes two different scenarios: 1) the event has not occurred at
time t, and 2) the event has occurred from a different cause before t. The difference between
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λj and λ∗j is due to the risk set. The former includes subjects who have failed from other
causes, but the latter excludes subjects who have failed from other causes up to time t.
Fine and Gray [23] suggested semiparametric proportional sub-distribution by adopting
the Cox proportional hazards model, which is following:
λj(t|Z) = λj0 exp(β′jZ), (1.3.7)
where λj0 is an unspecified, nonnegative baseline subdistribution hazard and βj is a p vector
of unknown regression parameters. Also, the covariates are linear on a complementary log-
log transformed cumulative incidence function. They showed that the partial likelihood
approach is still valid for the estimation in complete data and censoring complete data and
proposed the weighted score function for the right censored data. Fine [24] generalized the
Fine and Gray model [23] by using a transformation of the cumulative incidence function to
have flexibility. Given the assumption that g(.) is a known and differentiable function, the
following model is considered:
g{Fj(t|Z)} = hj(t)− β′jZ, (1.3.8)
where hj(t) is the baseline failure probability, unspecified, invertible and strictly increas-
ing in t. By choosing g(x) = log{− log(1 − x)}, it gives the proportional subdistribution
model. However, the proposed estimation method is less efficient under this model. Also,
the proportional odds model with g(x) = logit(x) is specified.
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CHAPTER 2: SELF-TRIGGERING COX MODEL
FOR RECURRENT EVENT DATA
2.1 Introduction
Recurrent event data frequently arise when subjects may experience more than one event
during the observation period. For example, cystic fibrosis patients have have repeated
Pseudomonas aeruginosa infections, which are prognostic for progressive lung disease and
are highly associated with the mortality and morbidity in early life. The most common
approaches to modeling recurrent event data are the Andersen and Gill (AG) model [3], the
Prentice, Williams and Peterson total time (PWP-CP) and gap time (PWP-GT) models [4],
and the Wei, Lin and Weissfeld model (WLW) model [6]. Other models, such as Lee, Wei
and Amato model [25] based on the marginal Cox model or frailty models [26] may also
be considered. While these model specifications target different endpoints and may have
different interpretations, the methods have been compared in simulation experiments and real
data analyses in terms of model fit [5, 7, 8, 27, 28]. The application of such methods generally
ignores previous event history when modeling the risk of future events, with the focus on
the effects of baseline covariates, like treatment, on the recurrent event trajectory. The
incorporation of time-dependent covariates capturing this history may improve a model fit
and prediction, but may also obscure the effects of time-independent covariates. Additionally,
it is difficult to deal with a large number of events when either of the PWP or WLW
approaches is applied.
There is limited literature discussing the potential use of event history for modeling the
occurrence of recurrent events. Recently, Chen and Chen [29] proposed an m-memory Cox-
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type self-triggering intensity model to account for the correlation among the occurrence of
events by utilizing a time-dependent decay function that describes the effects of previous
events. However, this work neither provides a formal statistical procedure to test if such
self-triggering effect exists, nor demonstrates the improvements that such effects may have
on model fit and the prediction of future event occurrences. This Chapter addresses these
issues.
The remaining sections are organized as follows. In Section 2.2, we briefly review the
Cox-type model with self-triggering scheme and discuss the use of partial likelihood for
parameter estimation and inference. In addition, we propose a hypothesis testing procedure
for the existence of the triggering scheme. Evaluation of model prediction is also discussed.
In Section 2.3, we will report simulation studies conducted to examine the feasibility of the
partial likelihood estimation and hypothesis testing procedures. The cystic fibrosis registry
data is analyzed in Section 2.4 with comparison between different modeling approaches in
terms of prediction accuracy.
2.2 Inference
2.2.1 Notations, Model, and Estimation
Let Tij denote the event occurrence time for the jth event of subject i, and let tij be the
observed realization of Tij. Letting Ci denote the censoring time, one can define Ni(t) =
N∗i (t∧Ci), where N∗i (t) is the number of events that are observed during the interval [0, t] for
subject i, and Yij(t) = I(Ci ≥ t), where I(A) is an indicator function of event A. Also, let
Zi = (Zi1, . . . , Zip)
′ denote the p-vector covariate with corresponding regression parameters
γ = (γ1, . . . , γp)
′ in a Cox-type regression model that also includes a non-increasing function
which accommodates the self-triggering effects of previous events. The intensity function is
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given by
λi(t) = λ0(t) exp
{
γ′Zi +
∫ t
0
ρ(t− s)dNi(s)
}
, (2.2.1)
where ρ is the self-triggering function that describes the decaying effects of previous events.
Assuming that ρ(x) = α exp(−βx) with unknown parameters α ≥ 0 and β ≥ 0, the model
(2.2.1) can then be written as
λi(t) = λ0(t) exp
γ′Zi + Ni(t−)∑
j=1
α exp{−β(t− tij)}I{Ni(t−) > 0}
 , (2.2.2)
where the parameter α controls the magnitude of the cumulative effects from previous events
and parameter β controls for the decay rate of the function. When α = 0, model (2.2.2)
assumes no self-triggering effects from previous events. The parameter values α 6= 0 and
β > 0 imply that more recent events have stronger effects than more distant events, while
α 6= 0 and β = 0 indicate non-differential effects from previous events and lead to a regular
Cox-type model with the total number of events, N(t−), as a time-varying covariate.
It is important to recognize that model (2.2.2) can be explosive. The intensity may
become arbitrarily large when either α is large or β is close to 0, and the process may
become non-stationary under these conditions. To address this issue, one may restrict to
bounded ρ by assuming there is no effect of previous events after either a certain time lag or
after a certain number of previous events. Chen and Chen [29] considered an m-lag model,
which is defined by
λi(t) = λ0(t) exp
γ′Zi + ∑
j∈`(t,m)
α exp{−β(t− tij)}
 , (2.2.3)
where `(t,m) = {j : max(N(t−) −m + 1, 1) ≤ j ≤ N(t−),m ∈ N+, N(t−) > 0}. That is,
the occurrence rate is influenced by the nearest m events in the history. Although m can be
predetermined by a researcher based on prior knowledge, it can also be determined from the
observed data based on cross-validation or likelihood based information measures, like the
Akaike information criterion (AIC). Of course, model (2.2.3) is equivalent to model (2.2.2)
as m→∞.
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Let ni denote the total number of observed events of subject i by Ci, i = 1, . . . , n. As-
suming Ci is independent of each Tij, conditionally on Zi, Chen and Chen [29] proposed a
partial likelihood function for θ = (γ, α, β)′, which is defined as
L(θ) =
n∏
i=1
ni∏
j=1
[
exp{φi(tij,m; θ)}∑
k∈R(tij) exp{φk(tij,m; θ)}
]dNi(tij)
, (2.2.4)
where φi(t,m; θ) = γ
′Zi +
∑
j∈`(t,m) α exp{−β(t− tij)} is the aggregated effects and R(tij) =
{k : Ck ≥ tij} =
∑
i Yij(tij) is the set of subjects who are at risk at time tij. The estimator
θˆ can be defined as a solution of ∂ log{L(θ)}/∂θ = 0. The large sample properties of θˆ
follow from standard partial likelihood theory given that the self-triggering function satisfies
certain regularity conditions. Thus, n1/2(θˆ − θ) is consistent and asymptotically zero mean
with covariance matrix Σ−1, where
Σ = E
[∫ τ
0
{
∂θφ(t,m; θ)− E[{∂θφ(t,m; θ)}Y (t) exp{φ(t,m; θ)}]
E[Y (t) exp{φ(t,m; θ)}]
}⊗2
Y (t)λ(t)dt
]
. (2.2.5)
The covariance matrix Σ can be consistently estimated with
Σˆ = n−1
n∑
i=1
∫ τ
0
{
∂θφ(t,m; θˆ)−
∑n
j=1{∂θφj(t,m; θˆ)}Yj(t) exp{φj(t,m; θˆ)}∑n
j=1 Yj(t) exp{φj(t,m; θˆ)}
}⊗2
× Yi(t) exp{φi(t,m; θˆ)}dΛˆ0(t)dt,
(2.2.6)
where Λˆ0(t) =
∫ t
0
dN¯(s)∑n
j=1 Yj(s) exp{φj(s,m;θˆ)}
, and N¯(s) =
∑n
i=1Ni(s).
2.2.2 Testing for Self-Triggering Effects
As mentioned previously, whether the event occurrence rate is independent of past events
is determined by the parameter α. Testing such assumption is of practical interest in under-
standing the natural history of disease. To test the assumption, one tests if α equals zero.
Under the null hypothesis α = 0, one may naively use likelihood-based methods such as like-
lihood ratio test, score test, or Wald-type test. However, when α = 0, the parameter β is not
identifiable in model (2.2.2). The classical large sample properties of these likelihood-based
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tests may not be valid under such non-identifiability [27, 30–32]. To avoid such issues, we
propose the following testing procedure.
Given a sequence of fixed β(k), k = 1, . . . , K < ∞, we estimate γ and α by maximizing
L(θ(k)) in (2.2.4), where θ(k) = (γ, α, β(k))′ when β = β(k). Let γˆ(k) and αˆ(k) denote the
maximizer of the function for γ and α, respectively. A Wald-type test statistic can be
defined by αˆ(k)/se(αˆ(k)), where se(αˆ(k)) denotes the standard error of αˆ(k). Under the null
hypothesis that α equals zero, the test statistic asymptotically follows a standard normal
distribution. However, to make a joint inference for α given different values of β, one requires
an adjustment for multiple testing. For simplicity, we adopt the Bonferroni correction to
account for multiple comparisons in these dependent hypothesis tests. If at least one p-value
is less than the predetermined size divided by K, the null hypothesis is rejected so that the
family-wise type I error probability can be controlled under the predetermined size. In the
simulations below, we study the performance of each individual testing result and compare
it with the overall procedure which adjusts for the multiple comparisons.
2.2.3 Prediction
Including event history as covariates is of importance for model specification, as well as
for model prediction for future events. Let pij(w; t) denote the probability of at least one
event occurring within a window (t, t+w], given that j events have occurred before t. Here,
w can be considered as a period of time when the occurrence of an event is of interest after
time t. One can show that the probability can be written as
pij(w; t) = P (Ti(j+1) ∈ (t, t+ w]|Tij ≤ t, Ti(j+1) > t)
= 1− Si(j+1)(t+ w)/Si(j+1)(t),
(2.2.7)
where Si(j+1)(t) = exp{−
∫ t
tij
λi(s)ds} is the conditional survival function of the (j + 1)th
event given that the jth event occurred at tij. If no event occurred before t, i.e., j = 0,
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we would let ti0 = 0 and Si1(t) = exp{−
∫ t
0
λi(s)ds} is the survival function of the time
to the first event. One may simplify pij(w; t) as pij(w; t) = 1 − exp{Λi(t + w; t)}, where
Λi(t+ w; t) =
∫ t+w
t
λi(s)ds is the cumulative hazard function in the window (t, t+ w]. One
can estimate pij(w; t) by
pˆij(w; t) = 1− exp{Λˆi(t+ w; t, θˆ)},
where Λˆi(t + w; t, θˆ) =
∫ t+w
t
dΛˆ0(s) exp{φi(s,m, θˆ)}ds with θˆ and Λˆ0 defined in Subsection
2.2.1.
To evaluate the performance of the prediction, one may apply the receiver operating
characteristic curve (ROC) for binary classification. This curve is created by plotting true
positive rate (sensitivity) against false positive rate (1-specificity) at various threshold prob-
abilities. Given a threshold probability q, one predicts at least one event would occur in
(t, t + w] if pˆij(w; t) > q. Let δi = I{pˆij(w; t) > q} denote the indicator of the predicted
event occurrence. The true positive rate under q is estimated by n−1∆
∑n
i=1 I(δi = ∆i), where
∆i = I{Ni(t+w)−Ni(t) > 0} and n∆ =
∑n
i=1 ∆i, while the false positive rate is estimated
by n−1∆
∑n
i=1 I(δi = 1−∆i). To summarize the accuracy of a model, an area under the curve
(AUC) may be calculated. However, when two ROC curves are compared, one may not be
interested in the entire range of the false positive rate. As an alternative, the partial AUC
that considers the area under only a portion of the ROC curve may be calculated and may
be more clinically relevant [33].
2.3 Simulation Studies
Extensive simulation experiments were conducted to demonstrate the feasibility of our
proposed method. We considered sample sizes n = 100, 400, 1000 with different α, β, and m.
For subject i, the recurrent event process was generated under the intensity function (2.2.3)
with λ0(t) = 1. We generated the first event time ti1 by solving the equation ti1 exp(γzi) +
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log(ui1) = 0, with subsequent event times obtained recursively by solving the equation
∫ ti`
ti(`−1)
exp
γ′zi + ∑
j∈`(t,m)
α exp{−β(t− tij)}
 dt+ log(ui`) = 0,
for ti`, ` = 2, . . . , ni, until ti(ni+1) is larger than the censoring time Ci, with ui` independently
drawn from a uniform distribution on the interval (0,1), and Ci randomly drawn from a
uniform distribution on the interval (0,4). The covariate zi = 1 if i is even, and 0 otherwise.
Table 2.1 shows the simulation results when γ = −0.5, α = 0.5, and β = 0.5, 1, with
each scenario replicated 1, 000 times. We report mean (MEAN), median (MED), empirical
standard deviation (ESD), defined by the sample standard deviation of the replicated esti-
mates, average of the replicated standard deviation estimates (ASD), and empirical coverage
probability (CP) at a 0.95 nominal level. In Table 2.1, the estimated γ and α have biases
close to 0 but the bias of β is relatively large when m = 1 and n = 100. However, the
median of the repeated estimates for β is close to the true value under this small sample
size. The bias decreases as the sample size increases and the number of lags increases. The
variance estimation is generally close to the empirical variance, with the empirical coverage
probability close to the nominal level.
Table 2.2 shows the simulation results for testing α = 0 when the true α = 0, 0.1, 0.2,
with γ = −0.5, β = 0.5 and m = 2. We implemented our hypothesis testing procedure
that addresses the potential non-identifiability issues. The sample size n ranges from 100 to
1,000. We choose five different β values and estimate γ and α with β fixed at one of those
five values. We report the average estimated values for γ and α from 1,000 repeated data
generations. The empirical size of the test (size), defined as the percentage of rejections
when the null hypothesis is true, i.e., α = 0, and the empirical power (power), defined as
the percentage of rejections when the null hypothesis is false, i.e., α 6= 0, are shown in Table
2.2. Regardless of the true value of β, the mean estimates of α increases as the given β
increases. The bias of αˆ is the smallest when β equals the true value except when α = 0. As
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Table 2.1: Simulation Results when γ = −0.5, α = 0.5, and β = 0.5 (first half), β = 1
(second half)
m 1 2 3 4
n 100 400 1000 100 400 1000 100 400 1000 100 400 1000
MEAN -0.50 -0.50 -0.50 -0.51 -0.50 -0.50 -0.51 -0.50 -0.50 -0.51 -0.50 -0.50
MED -0.50 -0.50 -0.49 -0.50 -0.50 -0.50 -0.51 -0.50 -0.50 -0.51 -0.51 -0.50
γˆ ESD 0.14 0.07 0.04 0.14 0.06 0.04 0.13 0.06 0.04 0.13 0.06 0.03
ASD 0.15 0.07 0.04 0.14 0.06 0.04 0.13 0.06 0.04 0.13 0.06 0.04
CP 95 94 95 94 95 95 95 95 94 95 94 94
MEAN 0.52 0.49 0.49 0.50 0.49 0.49 0.49 0.49 0.49 0.49 0.49 0.49
MED 0.52 0.50 0.50 0.50 0.50 0.49 0.49 0.49 0.49 0.49 0.49 0.49
αˆ ESD 0.21 0.09 0.06 0.11 0.05 0.03 0.08 0.03 0.02 0.05 0.02 0.01
ASD 0.21 0.10 0.06 0.11 0.05 0.03 0.08 0.03 0.02 0.05 0.02 0.01
CP 95 95 95 94 94 95 95 95 94 94 96 94
MEAN 1.19 0.56 0.52 0.62 0.51 0.49 0.53 0.49 0.49 0.49 0.49 0.49
MED 0.49 0.49 0.49 0.48 0.49 0.48 0.46 0.48 0.48 0.47 0.49 0.49
βˆ ESD 4.97 0.44 0.25 0.69 0.23 0.13 0.37 0.15 0.09 0.25 0.11 0.07
ASD 6.43 0.48 0.25 0.76 0.22 0.13 0.37 0.15 0.09 0.25 0.11 0.07
CP 90 93 94 93 93 95 93 93 93 93 94 94
MEAN -0.51 -0.49 -0.50 -0.51 -0.50 -0.50 -0.51 -0.50 -0.50 -0.51 -0.50 -0.50
MED -0.51 -0.49 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.51 -0.50 -0.49
γˆ ESD 0.15 0.07 0.04 0.14 0.07 0.04 0.14 0.06 0.04 0.14 0.07 0.04
ASD 0.15 0.07 0.04 0.14 0.07 0.04 0.14 0.07 0.04 0.14 0.07 0.04
CP 94 93 95 94 94 95 95 96 95 95 94 94
MEAN 0.53 0.50 0.50 0.51 0.50 0.49 0.49 0.49 0.49 0.49 0.49 0.49
MED 0.53 0.50 0.50 0.51 0.50 0.49 0.49 0.49 0.49 0.49 0.50 0.49
αˆ ESD 0.27 0.10 0.06 0.14 0.06 0.04 0.10 0.04 0.03 0.08 0.04 0.02
ASD 0.24 0.10 0.06 0.14 0.06 0.04 0.10 0.04 0.03 0.08 0.03 0.02
CP 94 94 95 94 95 95 93 96 93 95 94 95
MEAN 2.39 1.14 1.05 1.47 1.04 1.02 1.13 1.00 0.99 1.04 1.02 1.00
MED 0.97 0.94 0.98 1.01 0.98 1.00 0.98 0.98 0.98 0.97 1.00 0.99
βˆ ESD 7.05 0.97 0.45 3.31 0.38 0.23 1.10 0.28 0.18 0.53 0.23 0.14
ASD 6.38 0.95 0.44 2.43 0.41 0.24 0.92 0.29 0.17 0.57 0.23 0.14
CP 88 91 92 90 93 95 91 94 94 93 93 94
expected, the likelihood ratio test (LRT) has an inflated type-I error probability when the
null hypothesis is true, since the usual regularity conditions are not satisfied. We observe
the conservativeness of the Bonferroni correction (BC) under the same scenario, with the
empirical size well below the nominal level. The statistical power of the Boferroni correction
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Table 2.2: Simulation Results for Hypothesis Testing H0 : α = 0
n 100 400 1000
β γˆ αˆ power γˆ αˆ power γˆ αˆ power
0 -0.510 -0.012 5.2 -0.501 -0.001 4.0 -0.499 -0.002 4.9
0.25 -0.510 -0.014 5.5 -0.501 -0.001 3.6 -0.499 -0.003 5.0
0.5 -0.510 -0.016 5.1 -0.501 -0.001 4.3 -0.499 -0.004 4.8
0.75 -0.510 -0.017 5.3 -0.501 -0.001 4.5 -0.499 -0.005 4.7
1.0 -0.509 -0.018 4.7 -0.501 -0.001 4.3 -0.499 -0.006 5.2
BC 1.6 1.3 1.8
LRT 6.4 6.2 6.3
0 -0.506 0.061 9.7 -0.506 0.075 27.1 -0.499 0.075 57.7
0.25 -0.504 0.073 9.8 -0.504 0.089 30.3 -0.497 0.089 61.3
0.5 -0.503 0.082 10.7 -0.504 0.098 31.5 -0.498 0.098 62.3
0.75 -0.503 0.087 10.8 -0.505 0.104 30.8 -0.498 0.103 62.0
1.0 -0.504 0.091 10.3 -0.506 0.108 29.9 -0.500 0.107 60.6
BC 4.3 18.3 43.7
LRT 8.9 30.8 51.9
0 -0.510 0.154 29.7 -0.510 0.150 80.5 -0.504 0.151 99.2
0.25 -0.506 0.180 32.5 -0.506 0.176 84.9 -0.501 0.176 99.4
0.5 -0.506 0.196 33.7 -0.506 0.192 87.0 -0.500 0.192 99.5
0.75 -0.507 0.206 33.5 -0.507 0.202 86.1 -0.502 0.203 99.3
1.0 -0.509 0.213 33.7 -0.509 0.209 85.1 -0.504 0.210 98.9
BC 19.0 71.0 98.5
LRT 25.7 72.5 99.0
γ = −0.5, β = 0.5, and α = 0 (first part), α = 0.1 (second part), α = 0.2 (third part)
tends to be lower than the likelihood ratio test when the null hypothesis is false, especially
when the sample size is small. In contrast, the individual Wald tests with a given β have
size close to 0.05 and have the highest powers in every scenario. This occurs because of the
high correlation of the test statistics at different values of β, exceeding 0.90 for all pairs of
β offering providing modest gains in power.
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2.4 Analysis of Cystic Fibrosis Registry Data
Cystic fibrosis (CF) is an inherited disease of the secretory glands that causes thick and
sticky mucus in lungs and blocks airways. The buildup of mucus facilitates bacterial growth
in the lungs and repeated lung infections are common amongst CF patients. The most
common pathogen observed in the lungs of CF patients is Pseudomonas aeruginosa (Pa)
[34]. Recurrent Pa infections may be used to characterize the progression of chronic lung
disease in young CF patients.
In the 2007 CF Registry data, there are 6, 823 subjects who were born after 1997 and
had at least one follow-up before the end of year 2007. We considered gender, genotype,
and a diagnostic group as the time-independent covariates. Among those patients, 50.3%
were male. Regarding genotype, 68.8% were homozygous (∆F508/∆F508), 25.1% had a
severe mutation in their genotype (∆F508/non-∆F508-I, II, III), and 6.1% had a mild mu-
tation in their genotype (∆F508/non-∆F508-IV, V). The diagnostic group was defined by
the method of diagnosis of CF. Among the CF registry patients, 23.9% were diagnosed
by prenatal/neonatal screening (SCREEN), 18.6% were diagnosed by meconium ileus (MI),
5.7% were diagnosed by positive family history (FH), and 51.6% were diagnosed based on
symptoms other than meconium ileus (SYMPTOM). We chose homozygous genotype and
prenatal/neonatal screening groups as the reference categories for the genotype and diagnos-
tic group variables, respectively. We excluded patients without complete information. The
majority of patients who have missing data lack genotype information. The analysis below
included 4, 590 individuals.
We applied and compared five different modeling approaches including AG, PWP-CP,
PWP-GT, WLW and self-triggering Cox (STC) models. The AG model is a generalization
of the proportional hazards model to the intensity function of the repeated events which
assumes that the time-independent covariates have multiplicative effects. This model only
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can introduce the influence of the prior events on future recurrences through the time-
dependent covariates. The corresponding intensity function is given by
λi(t) = λ0(t) exp{γ′Zi}
with the risk set indicator Yis(t) = I(Ti,s−1 < t ≤ Tis) for s = 1, . . . , S, S = ni + 1 and the
risk set at time t by
∑
is Yis(t). Prentice, Williams, and Peterson employed stratified AG
models by considering two different time scales, a total time from the beginning of the study
and a gap time from the most recent preceding occurrence of an event. The PWP models
have restricted risk sets, i.e, the risk set for the (s + 1)th event contains only subjects who
have experienced s events and have stratum-specific hazards. The total time (PWP-CP)
and gap time (PWP-GT) models are given, respectively, as follows:
λis(t) = λ0s(t) exp{γ′sZis}
and Yis(t) = I(Ti,s−1 < t ≤ Tis), and
λis(t) = λ0s(t− ts−1) exp{γ′sZis}
and Yis(t) = I(Tis − Ti,s−1 > t), where λ0s is an unspecified event-specific baseline hazard
function for the sth event, Ti0 = 0 and TiS = Ci. The corresponding risk set at time t for
each stratum s is
∑
i Yis(t). Thus, as s increases, the number of subjects in the risk set may
decrease dramatically and it may be difficult to obtain stable parameter estimates for large
values of s. The WLW model is based on the marginal Cox models. That is, each event is
separately modeled on the total time scale with estimation within a given stratum ignoring
information in other strata. To accommodate the dependence between the recurrent event
times, a robust sandwich covariance matrix estimate is obtained. The hazard functions can
be written
λis(t) = λ0s(t) exp{γ′sZis}
with Yis(t) = I(Tis ≥ t) and the risk set at time t in the sth stratum is
∑
i Yis(t). This
method also has instability issues when the risk set becomes small for larger s. Finally, as
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we mentioned in Section 2.2.1, the proposed STC model can be regarded as a generalized
Cox-type model represented by the hazard function (2.2.3) with additional parameters α, β,
and optionally m.
We divided the 4, 590 subjects into two groups: a training group and a test group. We
randomly selected 3, 590 subjects as a training set for model estimation and building, and
then used the rest of the subjects as a test set for the evaluation of prediction. The average
number of events per subject in the training set is 1.8, with one individual having 39 repeated
infections. Thus, the maximum number of possible strata based on the previous number of
events for PWP and WLW methods is 40. Very few subjects would appear in some later
strata if one uses a highly stratified approach. Several modifications have been proposed to
deal with this issue [7, 35]. Firstly, one may ignore the risk set size issue and keep all strata in
the analysis despite the fact that the within-strata hazard estimates are unstable. Secondly,
one may delete the data after a certain number of events. Thirdly, one may aggregate the
strata with a small number of subjects, especially those with a high frequency counts. Since
among the 40 possible strata, 23 strata have less than 10 subjects, we adopted the third
approach when applying PWP and WLW. We considered the two different strata schemes,
denoted by s1 and s2, respectively. Up to the third event in s1 and the fifth event in s2,
each stratum (event) has its own stratum-specific regression coefficients. However, a single
model is considered for the later events.
For the conventional PWP and WLW methods, one can have either an overall estimate or
event-specific estimates for the covariate effects. For WLW, the overall estimate is obtained
as the weighted average of the event specific estimates minimizing the corresponding variance,
while for PWP, the overall estimate is obtained by fitting a single model to all events with
the same covariates. We chose six different lag numbers (m = 1, 2, 3, 4, 5,∞) under the STC
model. The estimation results under different models are shown in Table 2.3. To choose the
number of lags (m) in the self-triggering models, −2 log{L(θˆ)} values were calculated, where
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Table 2.3: Parameter Estimates under Various Models.
Gender Severe Mild MI FH SYMPTOM α β
Model (0:male)
STC
m=1 0.121* -0.020 -0.395* -0.048 -0.119* 0.013 1.731* 0.603*
(0.024) (0.028) (0.073) (0.041) (0.060) (0.029) (0.033) (0.031)
m=2 0.112* -0.025 -0.386* -0.047 -0.116 0.011 1.106* 0.549*
(0.024) (0.028) (0.073) (0.041) (0.060) (0.029) (0.021) (0.028)
m=3 0.110* -0.023 -0.390* -0.052 -0.118* 0.003 0.867* 0.514*
(0.024) (0.028) (0.073) (0.041) (0.060) (0.029) (0.017) (0.028)
m=4 0.107* -0.025 -0.389* -0.058 -0.126* -0.006 0.743* 0.478*
(0.024) (0.028) (0.073) (0.041) (0.060) (0.029) (0.016) (0.027)
m=5 0.106* -0.027 -0.396* -0.063 -0.130* -0.015 0.660* 0.452*
(0.024) (0.028) (0.073) (0.041) (0.060) (0.029) (0.016) (0.027)
m=∞ 0.094* 0.001 -0.448* -0.097 -0.178* -0.082* 0.560* 0.801*
(0.025) (0.029) (0.074) (0.042) (0.061) (0.029) (0.020) (0.041)
AG 0.176* -0.038 -0.595* -0.114 -0.245* -0.042
(0.031) (0.036) (0.088) (0.052) (0.075) (0.037)
PWP-CP 0.121* -0.023 -0.374* -0.026 -0.081 0.070*
(s1) (0.028) (0.032) (0.083) (0.049) (0.069) (0.034)
0.110* -0.031 -0.356* -0.038 -0.102 0.051
(s2) (0.028) (0.032) (0.082) (0.048) (0.069) (0.033)
PWP-GT 0.106* -0.026 -0.370* -0.046 -0.113 0.002
(s1) (0.025) (0.028) (0.076) (0.043) (0.060) (0.029)
0.102* -0.031 -0.358* -0.046 -0.122* -0.010
(s2) (0.024) (0.028) (0.076) (0.042) (0.059) (0.029)
WLW 0.178* -0.054 -0.660* -0.144 -0.339* -0.130*
(s1) (0.048) (0.055) (0.137) (0.078) (0.113) (0.054)
0.198* -0.051 -0.698* -0.164* -0.355* -0.125*
(s2) (0.052) (0.061) (0.143) (0.083) (0.123) (0.060)
†Estimated standard errors in parentheses.
†† Superscript * indicates that the corresponding p-value is less than 0.05.
a model with a smaller −2 log{L(θˆ)} value is preferred. The corresponding −2 log{L(θˆ)}
values for each m are 100266, 100027, 99974, 99931, 99937, and 100388 for m = 1, . . . , 6,
respectively. The smallest value occurs when m = 4, suggesting that the four most recent
31
events be used in the STC model.
To test the existence of the self-triggering effect, the Bonferroni correction method was
used. When fitting the STC model with m = 4, referred to as STC(4), we estimated
other parameters with β fixed at five different values, 0, 0.25, 0.478, 0.75, and 1.0, which is
centered at the β estimate in the selected STC model. Five Wald-type test statistics and their
corresponding p-values for α = 0 were calculated. All five p-values are less than 0.01, which
suggests that the self-triggering effect is statistically significant. The coefficient of gender
γˆ1 = 0.110 indicates that the estimated relative risk for Pa infection is exp(0.110) = 1.116.
That is, the Pa infection is more likely to occur in females than in males. Similarly, one
can conclude that the infection is less likely to occur in the mild mutation genotype group
compared to the homozygous group and in the patients who are diagnosed via family history
compared to the patients diagnosed by prenatal or neonatal screening. The same conclusions
about covariate effects can be drawn under the AG model. The other models evidence
somewhat different results even within the same stratification schemes. Additionally, we
note that the coefficient estimates under the WLW model are greater than those from other
competing models. Total time models, such as AG, PWP-CP, WLW, and STC tend to
produce larger estimated covariate effects. This may occur because total times within a
patient may be highly correlated, resulting in a carry-over effect. Such effects have been
previously documented with the WLW model [5, 36–38].
The model prediction using the test set with 1,000 subjects was implemented using the
fitted models from the training set, where possible. The estimated probability of a new
event occurring during 2004 is calculated based on data at the end of 2003. Among 1, 000
subjects in the test data, we do not consider 456 subjects who are censored before 2004.
Also, the WLW method is based on the marginal models which do not provide the estimated
predictions. The left panel of Figure 2.1 displays ROC curves and AUC values of each model,
while the right panel is a zoom-in on the portion of the ROC curves where the false positive
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Figure 2.1: ROC curves and partial ROC curves
Table 2.4: Two Paired ROC Curves Comparison Tests’ p-values by AUC and pAUC
Model M1 M2 M3 M4 M5 M6 M7 M8 M9
M1: STC(1) <.001 <.001 <.001 .002 .803 .113 <.001 <.001
M2: STC(2) .001 .091 .187 <.001 .013 .190 .408 .484
M3: STC(3) .004 .301 .936 <.001 .002 .040 .044 .067
M4: STC(4) .013 .646 .504 <.001 <.001 .024 .035 .045
M5: AG <.001 <.001 <.001 <.001 .001 <.001 <.001 <.001
M6: PWP-CP(s1) .649 .050 .015 .011 <.001 .050 .028 .024
M7: PWP-CP(s2) .880 .102 .037 .030 <.001 .175 .390 .255
M8: PWP-GT(s1) .009 .797 .788 .948 <.001 .013 .037 .782
M9: PWP-GT(s2) .012 .867 .694 .857 <.001 .014 .035 .832
rate is less than or equal to 0.2.
We used the test method proposed by [39] for the comparison of the AUC and partial
AUC using bootstrapped variance estimation [40]. The corresponding null hypothesis is
H0 : A1 = A2 and the alternative hypothesis is H0 : A1 6= A2, where A1 and A2 are the two
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(partial) AUCs. All possible tests for the pairwise model comparisons are performed. Table
2.4 shows the corresponding p-values. Specifically, the lower triangular values represent p-
values for the AUC comparisons, while the upper triangular values represent p-values for
the partial AUC comparisons. The prediction performance of the STC(4) model is not
significantly different from the PWP gap time model in terms of AUC, using either 4 (s1) or
6 (s2) strata. However, the underlined p-values in Table 2.4 indicate that the partial AUC
of the STC(4) model is significantly different from all other competing models, including
PWP gap time model. The STC(3) model has AUC and pAUC that are quite comparable
to STC(4) and are significantly different from those for the non-STC models in Table 2.4.
2.5 Discussion
In this Chapter we examined the Cox model with self-triggering effects for recurrent event
data, and compared the model to the currently existing methods. To test the existence of
the self-triggering effect, the parameter beta describing the decay rate of the triggering effect
was fixed with other unknown parameters estimated and used to construct a test statistic.
This can address the non-identifiability of the STC model under the null of no triggering
effect. The Bonferroni correction procedure was proposed to adjust for multiple testing at
different values of beta. Interestingly, the adjustment appears to be rather conservative,
with the simulations indicating that tests at fixed beta are highly correlated and a test at
a single beta may provide greater power than the multiple testing approach. This requires
further investigation. As an alternative, supremum score tests have been advocated in other
testing scenarios with non-identifiability under the null and might be utilized in the current
setting [30–32]. This is a topic for future research.
In analysis of the cystic fibrosis data, we demonstrated that the extended Cox model with
a self-triggering scheme may yield significant gains in prediction of future events compared
to available models. One particular characteristic of this dataset is that it includes fairly
34
large number of infections per subject, which creates difficulties in defining strata for the
PWP and WLW methods. The STC model accommodates such data more naturally, with a
growing number of recurrent events easily accommodated by the intensity function (2.2.3).
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CHAPTER 3: COX MODEL FOR RECURRENT EVENT DATA
WITH INSTRUMENTAL VARIABLE
3.1 Introduction
Recurrent failure events are frequently considered in a longitudinal study when subjects
could possibly experience more than one event during the observation period. To explore the
relationship between the effects of covariates and the correlated failure times, the Anderson-
Gill (AG) model is commonly applied. However, when some patients do not adhere to their
assigned treatments in a randomized trial, the standard intention-to-treat (ITT) analysis,
which focuses on the causal effect of assignment of treatment rather than the causal effect
of receipt of treatment, may not properly estimate the effect of treatment on the outcome.
Another naive method is analyzing with received treatment. It is likely to be confounded
by determinants of compliance [41]. The use of instrumental variable methods helps us to
consistently estimate the average causal effect of an exposure on some outcome of interest
even in the presence of latent confounding. Abadie [42] suggested new IV estimators for
general response models with covariates. In this Chapter, we will apply the weighting scheme
of Abadie [42] into the Cox and AG models for analyzing survival data with non-informative
right censoring. We demonstrate our approach via comprehensive simulation studies and a
colorectal-cancer screening data analysis.
Instrumental variable (IV) methodology is one approach to deal with the issue of unmea-
sured confounders. It has been actively explored and discussed over the last few decades in
the econometrics, epidemiology, statistics, and biomedical sciences [10, 41, 43–46].
An important application of IV methods is to estimate the effect of receiving treatment
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in randomized trials with non-adherence, i.e., some individuals do not comply with the
assignment treatment. When there is noncompliance, the standard intention-to-treat (ITT)
effect is different from the effect of receiving the treatment versus the control. Since the
ITT measures the effect of assignment of treatment rather than the effect of actual receipt
of treatment [42, 45, 47–49].
A special type of noncompliance, all-or-nothing (all-or-none) compliance, is that all sub-
jects are immediately categorized whether they comply or not with their assigned treatment
after randomization. That is, there is no partial compliance in this situation [50]. In con-
trast, an application in partial compliance requires strong assumptions for identifiability.
Thus, the all-or-none compliance status is commonly considered [14, 18, 47, 48, 50, 51].
To deal with survival outcome under noncompliance, several methods have been devel-
oped and implemented. Baker [51] suggested a likelihood-based approach for discrete time
survival data to estimate the difference between complier hazards in treatment and con-
trol group by considering death as competing risk. Loeys and Goetghebeur [14] proposed
the marginal structural Cox proportional hazards model for a compliers proportional haz-
ards effect of treatment and derived estimating equation for it under independent censoring.
However, they did not consider covariates, that is a generalization of the Mantel-Haenszel
estimator. Cuzick et al. [19] applied a partial likelihood method by accommodating covari-
ates by assuming independence of covariates and compliance class. Also, they explored a full
likelihood when covariates are not independent of compliance, but it was too complicated to
estimate. Gong [50] developed several parametric potential outcome survival models with
considering ignorable and non-ignorable censoring schemes. Based on Baker [51] and Nie
et al. [52] estimated the effect of treatment on survival at specific times by adopting a non-
parametric approach in the presence of noncompliance and administrative censoring. Nie
et al. [52] included always-takers, unlikely that Baker [51] only considered compliers and
never-takers. Additionally, they gained efficiency over the standard IV method by using the
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mixture structure in the data. Lin et al. [53] considered a semi-parametric linear transfor-
mation model and proposed a two-stage estimation procedure to estimate the parameters.
MacKenzie et al. [54] extended Cox’s proportional hazards model by adding additional ad-
ditive term into intensity function by assuming approximate orthogonality of an instrument
with latent confounders. Thus, they derived an estimator from the score equation of the
partial likelihood similar to Cox model. Yu et al. [18] used semi-parametric transformation
models for the distribution of survival time, conditionally on covariates and latent compli-
ance type. Maximum likelihood is used to estimate the parameters of the transformation
models and applied expectation-maximization (EM) algorithm to overcome the computa-
tional difficulties from the mixture structure and the infinite dimensional parameter in the
models. They considered the complier average causal effect, the complier effect on survival
beyond time t, and the complier quantile effect. Like Cuzick et al. [19], they also allow
for always-takers with a positive probability but they allow the association between covari-
ates and response to vary with compliance class. A few papers have considered trials with
repeated outcome measures in the presence of noncompliance. Yau et al. [55] extended
Imbens and Rubin [56] by allowing the baseline covariates and missing in outcomes, Small
et al. [57] proposed a random effects model approach for longitudinal binary outcomes, and
OMalley [58] presented the concept of lagged predictors and outcomes to incorporate IV in
longitudinal analysis.
The remaining sections are organized as follows. In Section 3.2 we introduce notation,
model, estimand and IV assumptions mostly based on [42] and describes the method of
estimation and asymptotic properties of the estimators. To demonstrate the feasibility of
our proposed method, simulation studies are presented in Section 3.3. In Section 3.4, we
apply the method into the colorectal- cancer data from Prostate, Lung, Colorectal, and
Ovarian (PLCO) cancer screening trial to evaluate the effect of flexible sigmoidoscopy in
comparison with usual care on colorectal-cancer mortality.
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3.2 Inference
3.2.1 Notations, Assumptions and Models
We consider two-armed randomized trials with all-or-nothing compliance and repeated
failure time outcomes. Let X be a p-dimensional covariate vector. Suppose that Z is a
binary instrument variable. If a subject is assigned to the control group then Z = 0, and
if a subject is assigned to the treatment group, then Z = 1. Dz is a potential treatment
status given Z = z. That is, under assignment Z = z, Dz = 1 represents a particular subject
would take the treatment, but would not be given the treatment otherwise. The observed
treatment status binary variable can be expressed as D = ZD1 + (1 − Z)D0. Similarly, let
Tzd denote the potential event time vector when Z = z and D = d.
Clearly, if D0 = 0, we are only able to observe T00 not T01 without considering censoring.
Let L = l be the indicator of the potential compliance stratum. There are four different types
given by [56] such as compliers, always-takers, never-takers, and defiers. By convention, the
values L = 1, 2, 3, 4 refer to compliers, always-takers, never-takers, and defiers respectively.
Since we cannot fully observe potential outcome vector, compliance type is also unobservable.
These four compliance types can be written with using Dz as follows,
L =

1 if D0 = 0 and D1 = 1
2 if D0 = 1 and D1 = 1
3 if D0 = 0 and D1 = 0
4 if D0 = 1 and D1 = 0.
We now make the following assumptions akin to [42]:
Assumption 3.2.1. random assignment conditional on covariates
(D0, T00, T01, D1, T10, T11) |= Z|X, where |= denotes independence.
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Assumption 3.2.2. conditional monotonicity
P (D1 ≥ D0|X) = 1.
Assumption 3.2.3. exclusion restriction
P (T0d > t|X) = P (T1d > t|X) for all t and d ∈ {0, 1}.
Assumption 3.2.1 is a weaker assumption than (D0, T00, T01, D1, T10, T11, X |= Z)
in a complete randomization setting. That is, it means that there is no other common
factors of the IV and the outcome. Assumption 3.2.2 implies that there are no defiers.
This assumption is based on consistent preference [46] and it is a key assumption under
heterogeneous treatment effects [10]. Assumption 3.2.3 says that the probability of outcome
does not depend on treatment in always-takers and never-takers strata since they receive
the same treatment regardless of assignment; the experiment provides no information about
the treatment effect in these strata. Thus, we can write Td ≡ Tzd for any z. That is, it
guarantees that Z is not able to make an effect on the outcome directly only through the
treatment status (D).
Assumption 3.2.4. conditional first stage
0 < P (Z = 1|X) < 1 and P (D1 = 1|X) > P (D0 = 1|X).
Assumption 3.2.5. independent censoring
(Z,D, T ) |= C, where C is the censoring time.
In addition to these assumptions, Abadie [42] presents a Lemma 2.1 an identification
Theorem 3.1 summarized as following: Let g(.) be any measurable real function of (Y,D,X)
such that E|g(Y,D,X)| <∞, where Y is an outcome of interest. Define
κ = 1− D(1− Z)
P (Z = 0|X) −
(1−D)Z
P (Z = 1|X) ,
and under the previous assumptions,
E[g(Y,D,X)|D1 > D0] = 1
P (D1 > D0)
E[κg(Y,D,X)].
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The κ can be considered as a weight that allows us to estimate expectations for compliers
in terms of expectations for the entire population. However, κ takes a negative value when
D is different from Z. Thus, we cannot directly use log partial likelihood as an objective
function in the estimation process. This will be discussed more detail in Section 3.2.
Let N∗(t) be the number of events that occur during the interval [0, t] and H(·) be a
(p + 1) dimensional covariate process including X and D. However, the observation period
is mostly limited by some predetermined time τ so N∗(·) cannot be fully observed. Let C
denote censoring time as previously defined. The censoring scheme is also assumed to be
independent such that E[dN∗(t)|H(t), C ≥ t] = E[dN∗(t)|H(t)] for all t ≥ 0. Anderson and
Gill [3] suggested the following intensity model such as
λ(t) = λ0(t) exp{β′1X + β2D}, (3.2.1)
where λ0(·) is an unspecified baseline hazard function, β1 is a p-dimensional coefficient vector
for X and β2 is a scalar coefficient for D. These regression coefficients measure the effects of
the corresponding covariates to the intensity on the log scale. Here, we only consider time
invariant covariates, i.e., H(t) = H. Since Z and D for compliers, Z is ignorable under the
Assumptions 3.2.1 and 3.2.3. Thus, we have
λ(T |D1 > D0, X,D = 1) = λ(T1|D1 > D0, X, Z = 1) = λ(T1|D1 > D0, X),
λ(T |D1 > D0, X,D = 0) = λ(T0|D1 > D0, X, Z = 0) = λ(T0|D1 > D0, X)
and
λ(T |D1 > D0, X,D = 1)
λ(T |D1 > D0, X,D = 0) =
λ(T1|D1 > D0, X)
λ(T0|D1 > D0, X) = exp(β2).
We consider this hazard function as a local hazard function defined as λ(T |D1 > D0, X,D).
The β2 is the parameter of interest and we refer to exp(β2) as the causal proportional hazards
effect corresponding to the conditions described by two levels of D within compliers.
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3.2.2 Estimation and Asymptotic Properties
Abadie [42] presented two methods to estimate parameters for LARF such as Least
Squares (LS) and Maximum Likelihood (ML). ML can be easily applied to the partial
likelihood to deal with time-to-event data, so it will be adopted in this paper. Define
N(t) = N∗(t ∧ C) and Y (t) = I{C ≥ t}, where a ∧ b = min(a, b), and I(·) is an in-
dicator function. Suppose that the observed data {Ni(·), Yi(·), Hi} for i = 1, . . . , n are
independent and identically distributed. Let’s denote ω(x) = P (Z = 1|X = x) as a
nuisance function for κ. If we know the function ω(x), then we can calculate κi with
κi = 1 − di(1 − zi)/{1 − ω(xi)} − (1 − di)zi/ω(xi). The following equation is a partial
likelihood after weighting by κ based on [3]
PL(θ) =
n∏
i=1
ni∏
j=1
{
κi exp(θ
′Hi)∑
k∈R(tij) κk exp(θ
′Hk)
}dNi(tij)
, (3.2.2)
where Hi = (X
′
i, Di)
′, θ = (β′1, β2)
′, j = 1, . . . , ni, and ni = Ni(Ci). As we mentioned in
Section 3.2, we cannot directly use this weighted partial likelihood as an objective function
for ML. Since κi can be negative values, taking the logarithm of this function is not valid.
Under Eq.(3.2.2), the corresponding weighted score function for θ is given by
Uκ(t; θ) =
n∑
i=1
κi
∫ t
0
{Hi − Eκ(s; θ)} dNi(s), (3.2.3)
where Eκ(s; θ) =
∑n
j=1HjYj(s)κj exp(θ
′Hj)∑n
j=1 Yj(s)κj exp(θ
′Hj)
.
Based on [42], the following assumption guarantees the usual identification condition.
Assumption 3.2.6. U(τ ; θ|D1 > D0) = 0 has a unique solution at θ0 over θ ∈ Θ, where τ
denotes the end of the study time, U(τ ; θ) =
∑n
i=1
∫ τ
0
{Hi − E(s; θ)}dNi(s), and E(s; θ) =∑n
j=1HjYj(s) exp(θ
′Hj)∑n
j=1 Yj(s) exp(θ
′Hj)
.
Then, the parameter θ0 can be estimated by θˆ the solution to the equation Uκ(τ ; θ) = 0
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with using Theorem 3.1 in [42]. This implies that n−1Uκ(θ) converges almost surely to a
function U(θ|D1 > D0), that is ‖Uκ(θ)− U(θ|D1 > D0)‖ −→a.s. 0.
As we mentioned, if we know the function ω0, then κi(di, zi, ω0(xi, γ0)) is observed and
θ0 can be directly estimated with a single step. However, ω(·) is commonly unknown in
practice. Therefore, we need one more step to estimate γ0 which could be estimated by
specifying a parametric model ω(X, γ). Suppose that we consider E[Z|X] = Φ(γ′X), where
Φ(·) is a standard normal cumulative distribution function. This probit linear model is often
used when the dependent variable is binary. Then, γ0 can be estimated by solving
∂
∂γ
n∑
i=1
{zi ln Φ(γ′xi) + (1− zi) ln Φ(−γ′xi)} = 0. (3.2.4)
Let γˆ denote the solution of the Eq.(3.2.4) and κi can be estimated by κˆi(γˆ) = κi(di, zi, ω(xi, γˆ)).
The weighted score function re-expressed by adding γ is following
Uκ(θ, γ) =
n∑
i=1
κi(γ)
∫ τ
0
[Hi − Eκ(s; θ, γ)] dNi(s), (3.2.5)
where Eκ(s; θ, γ) =
∑n
j=1HjYj(s)κj(γ) exp(θ
′Hj)∑n
j=1 Yj(s)κj(γ) exp(θ
′Hj)
. To obtain θˆ(γˆ), we solve Uκ(θ, γˆ) = 0. The
following regularity conditions are imposed to construct Theorem 3.2.1 and 3.2.2, for i =
1, . . . , n:
c1) P (Yi(τ) = 1) > 0.
c2) Ni(τ) are bounded by a constant.
c3) Hi are bounded and time invariant.
c4) Let S
(r)
κ (t; θ, γ) = n−1
∑n
i=1 H
⊗r
i Yi(t)κi(γ) exp(θ
′Hi) for r = 0, 1, 2, where for any vector
a, a⊗0 = 1, a⊗1 = a, and a⊗2 = aa′. Also, let Eκ(t; θ, γ) = S
(1)
κ (t; θ, γ)/S
(0)
κ (t; θ, γ), and
eκ(t; θ, γ) be the corresponding limit.
c5) Σθ = E
[∫ τ
0
κ(γ0){H − eκ(θ0, γ0)}⊗2Y (t) exp(θ′0H)dΛ0(t)
]
is positive definite.
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Theorem 3.2.1. (Consistency of θˆ)
Suppose that all Assumptions 3.2.1-3.2.6 and the regularity conditions previously listed and
that (i) ω(·) belongs to some parametric functions such that ω(X, γ) with ω0 = ω(X, γ0) for
some γ0 ∈ Rq; there exists η > 0 such that for ‖γ − γ0‖ < η, ω(X, γ) is bounded away
from zero and one and is continuous at each γ on the support of X; (ii) γˆ −→p γ0. Then
θˆ(γˆ) −→p θ0.
To establish the asymptotic normality of θˆ, we need to consider the corresponding distri-
bution of Uκ(θ0, γ0) =
∑n
i=1 κi(γ0)
∫ τ
0
[Hi − Eκ(s; θ0, γ0)] dMi(s), where dMi(s) = dNi(s) −
Yi(s) exp(θ
′
0Hi)dΛ0(s).
Theorem 3.2.2. (Asymptotic normality of θˆ)
Under the assumptions in Theorem 3.2.1, and (i) for ‖γ − γ0‖ < η, ω(X, γ) is continuously
differentiable at each γ, ∂ω(X, γ)/∂γ is bounded; (ii) γˆ is asymptotically linear with influ-
ence function ψ(B), i.e.,
√
n(γˆ − γ0) =
√
n
−1∑n
i=1 ψ(bi) + op(1), where E[ψ(bi)] = 0 and
E[ψ(bi)
′ψ(bi)] <∞. Then,
√
n(θˆ(γˆ)− θ0) −→d N(0,Σ), where
Σ = Σ−1θ E [{Uκ(θ0, γ0) + Σγψ}{Uκ(θ0, γ0) + Σγψ}′] Σ−1θ ,
Σθ = E[
∂
∂θ
Uκ(θ0, γ0)],Σγ = E[U(θ0, γ0){∂κ(γ0)/∂γ}],
and
U(θ0, γ0) =
n∑
i=1
∫ τ
0
{Hi − Eκ(s; θ0, γ0)}dMi(s).
The Σ can be consistently estimated by
Σˆ = Σˆ−1θ
[
1
n
n∑
i=1
{Uiκ(θˆ, γˆ) + Σˆγψˆi}{Uiκ(θˆ, γˆ) + Σˆγψˆi}′
]
Σˆ−1θ , where
Σˆθ = −n−1∂Uκ(θˆ, γˆ)/∂θ = n−1
n∑
i=1
∫ τ
0
κi(γˆ){Hi − Eκ(θˆ, γˆ)}⊗2Yi(s) exp(θˆ′Hi)dΛˆ0(s),
Uiκ(θˆ, γˆ) =
∫ τ
0
κi(γˆ){Hi−Eκ(s; θˆ, γˆ)}dMˆi(s), where dMˆi(s) = dNi(s)−Yi(s) exp(θˆ′Hi)dΛˆ0(s),
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Σˆγ = n
−1
n∑
i=1
∫ τ
0
{Hi − Eκ(s; θˆ, γˆ)}dMˆi(s){∂κi(γˆ)/∂γ}′.
The estimate for Uiκ is defined as the score residual for each subject and each variable [59].
The estimator of the cumulative baseline intensity function Λ0(t) =
∫ t
0
λ0(s)ds is similar to
the Breslow estimator in [60]. However, some κi’s are negative so it is given by
Λˆ0(t; θˆ, γˆ) =
∫ t
0
max
{ ∑n
i=1 κi(γˆ)dNi(s)∑n
i=1 κi(γˆ)Yi(s) exp(θˆ
′Hi)
, 0
}
. (3.2.6)
3.3 Simulation Studies
Extensive simulation experiments are explored in this section to demonstrate the feasi-
bility of our proposed method by comparing it with the existing method. We adopted the
ways to generate ui, di and tij based on [53] and [18]. For each subject i = 1, . . . , n, we do
the following steps:
1) Draw xi from some choice of f(x).
2) Draw zi from some choice of P (z = 1|x; γ). We chose P (z = 1|x) = Φ(γ′x), where Φ is
the cumulative distribution function (CDF) of the standard normal distribution.
3) Draw l from the multinomial distribution with probability p = (p1, p2, p3), in which l = 1
(compliers), 2 (always-takers), or 3 (never-takers), and the subgroup probabilities are
calculated by using the multinomial logistic regression model given by
pl = P (L = l|x;α) = exp(α0l + α
′
lx)
1 +
∑2
l=1 exp(α0l + α
′
lx)
, for l = 1, 2
, and p3 = 1− p1 − p2.
4) Determine di by f(z, l) = zI{l ≤ 2}+ (1− z)I{l = 2}.
5) Generate tij by applying different coefficients depending on potential class types.
a) Draw ri from the uniform distribution from 0 to 1.
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b) Solve the following equation to get a gap time gij,
3∑
m=1
gij exp(θ
′
lhi)I{li = l}+ log(ri) = 0, where hi = (xi, di)′.
c) Calculate tij = ti(j−1) + gij.
d) Recursively do step a)-c) while tij is less than some predetermined value τ .
6) Generate ci from the uniform distribution from 0 to τ .
As a brief illustration, we performed a simulation study where 1000 samples were generated
according to the aforementioned algorithm, each with n = 500, 1000, 2000 observations and
τ = 5. We considered two covariates except D. One is a binary variable drawn from
the binomial distribution with probability 0.5 and the other one is a continuous covariate
drawn from the truncated normal distribution whose range is from −2 to 2. By changing
the parameter α’s in step 3, we are able to adjust the proportion of compliers, p1. The
proportion of compliers can measure the strength of the IV which refers to how strongly
the IV is associated with the treatment after controlling for the measured confounders X
[10, 45]. We conducted simulations under two different p1’s ranges such as [.49, .68] and
[.61, .89]. Additionally, each stratum has a different θm, m = 1, 2, 3 in step 5 b), but we will
use the same value for m = 2 and 3 for simplicity. Since heterogeneity of treatment effects
is not restricted by the identification conditions in this IV model [42]. Data was generated
according to the assumptions that we have in Section 3.2.
Table 3.1 and 3.2 show the simulation results when θ1 = (β11c, β12c, β2c)
′ = (0.5, 0.5, 1.0)′
and θ2 = θ3 = (β11o, β12o, β2o)
′ = (0.3, 0.3, 0.5)′, with complier probability ranges [.49, .68]
and [.61, .89], respectively. The proposed IV model is compared with the AG models, 1)
with D; 2) with Z, i.e., ITT, in every six settings. The IV parameters are estimated by
using initial values from the AG model with D. We report mean (MEAN); median (MED);
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Table 3.1: Simulation Results with β11c = β12c = 0.5, β11o = β12o = 0.3, β2c = 1.0, β2o = 0.5
and p1 = [.49, .68].
Proposed IV Model AG Model AG Model (ITT)
N 500 1000 2000 500 1000 2000 500 1000 2000
MEAN 0.511 0.501 0.500 0.540 0.538 0.536 0.472 0.471 0.470
MED 0.504 0.498 0.497 0.536 0.538 0.536 0.470 0.470 0.471
X(β11c) ESD 0.199 0.106 0.069 0.068 0.049 0.036 0.070 0.051 0.036
TSD 0.191 0.109 0.074 0.069 0.049 0.035 0.059 0.042 0.029
CP 96.9 96.4 96.6 86.0 79.9 73.4 88.2 84.6 77.3
MEAN 0.518 0.503 0.503 0.480 0.481 0.481 0.433 0.433 0.434
MED 0.502 0.495 0.500 0.481 0.483 0.481 0.433 0.432 0.433
X(β12c) ESD 0.137 0.077 0.042 0.044 0.030 0.021 0.045 0.031 0.021
TSD 0.119 0.070 0.045 0.042 0.030 0.021 0.035 0.024 0.017
CP 94.9 95.2 96.0 82.1 79.1 73.2 50.0 25.2 7.8
MEAN 1.010 1.004 0.999 0.708 0.709 0.706 0.688 0.688 0.686
MED 1.005 1.008 0.998 0.708 0.709 0.707 0.687 0.690 0.686
D(β2c) ESD 0.115 0.075 0.053 0.068 0.046 0.032 0.074 0.049 0.036
TSD 0.123 0.082 0.053 0.066 0.046 0.033 0.060 0.042 0.030
CP 95.3 95.7 94.8 0.8 0 0 0.5 0 0
Outlier/No Convergence 22 9 3 0 0 0 0 0 0
empirical standard deviation (ESD), defined by the sample standard deviation of the repli-
cated estimates; average of the replicated theoretical standard deviation estimates (TSD);
and empirical coverage probability (CP) at a 0.95 nominal level. Additionally, we present
the number of outliers or no-convergence cases out of 1, 000 replications. The outliers are de-
fined by using the median absolute deviation (MAD), MAD(x) = b∗MED(|x−MED(x)|),
where b = 1.4826. If |xi −MED(x)|/MAD(x) is greater than 20, then we define xi as an
outlier. Table 3.1 and 3.2 contain all estimates based on the proposed IV method. The
estimates have biases close to 0 and the biases decrease as the sample size increases. The
estimated variances are similar to the corresponding empirical variances, so the empirical
coverage probabilities are close to the nominal level 95. In contrast, the biases by the naive
AG model are relatively large and do not noticeably decrease by increasing sample size.
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Table 3.2: Simulation Results with β11c = β12c = 0.5, β11o = β12o = 0.3, β2c = 1.0, β2o = 0.5
and p1 = [.61, .89].
Proposed IV Model AG Model AG Model (ITT)
N 500 1000 2000 500 1000 2000 500 1000 2000
MEAN 0.502 0.502 0.500 0.556 0.556 0.556 0.523 0.522 0.524
MED 0.496 0.497 0.500 0.557 0.556 0.555 0.526 0.523 0.524
X(β11c) ESD 0.116 0.074 0.052 0.065 0.044 0.033 0.072 0.050 0.035
TSD 0.110 0.074 0.051 0.062 0.044 0.031 0.059 0.042 0.030
CP 95.6 95.9 94.7 82.7 71.6 52.2 88.5 86.8 82.7
MEAN 0.504 0.500 0.502 0.490 0.488 0.489 0.475 0.473 0.473
MED 0.496 0.497 0.501 0.490 0.488 0.489 0.474 0.473 0.472
X(β12c) ESD 0.072 0.044 0.031 0.036 0.025 0.018 0.040 0.028 0.021
TSD 0.062 0.042 0.029 0.035 0.025 0.018 0.035 0.024 0.017
CP 96.1 95.8 94.5 91.6 91.0 87.0 83.4 77.3 62.7
MEAN 1.001 0.999 0.999 0.969 0.968 0.968 0.875 0.873 0.874
MED 0.999 0.999 1.000 0.966 0.968 0.968 0.875 0.874 0.874
D(β2c) ESD 0.079 0.054 0.037 0.061 0.042 0.029 0.068 0.046 0.032
TSD 0.079 0.055 0.038 0.060 0.042 0.030 0.059 0.042 0.029
CP 94.9 95.4 95.9 91.1 88.0 79.0 43.9 16.8 1.5
Outlier/No Convergence 2 2 0 0 0 0 0 0 0
Additionally, even though the variance estimation is close to the empirical variance, the
empirical coverage probability has a rather poor value due to bias. We expected intuitively
some values between 0.3 and 0.5 for the estimates of β11 and β12 in AG model. However,
the β12 is included in that range but not for the β11. The bias of β11 is even larger when the
compliance rate is higher. Through this simulation, we can also confirm that IV estimators
have a larger asymptotic variance than the conventional ones, since the IV introduces an
additional source of uncertainty. In terms of proportion of compliance, the less the rate of
noncompliance, the less the ITT effect and the average treatment effect among compliers
tend to differ, which is the same results in [10, 44, 45]. The number of outliers or divergence
cases decreases as the rate of compliance, or sample size increase. We also applied this pro-
posed method to the Cox proportional hazard model and present corresponding simulation
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results in the Appendix 5.
3.4 Colorectal-Cancer Mortality with Screening Flexible Sigmoidoscopy
Colorectal-cancer is cancer that initiates in the colon or rectum which are parts of the
large intestine. It is known as the second most common cause of cancer death in the United
States after lung cancer [61]. Screening is often suggested as one of the best way to protect
colorectal-cancer. Because it can early detect precancerous growths, called polyps, that can
transform into cancer. There are several recommended screening options, such as fecal occult
blood test (FOBT), fecal immunochemical test (FIT), colonoscopy, virtual colonoscopy or
flexible sigmoidoscopy.
The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial is a multi-
center, two-armed randomized trial, sponsored by the National Cancer Institute, of screening
tests for prostate, lung, colorectal and ovarian cancers. Ten centers across the U.S. recruited
participants between November 1993 and July 2001. Data were collected until December 31,
2009. One objective of the trial is evaluating the effectiveness of the screening with flexible
sigmoidoscopy on mortality from colorectal-cancer by comparing with usual-care. Prorok
et al. reported further details about this trial [62].
The original data consist of 154, 897 individuals aged 55 to 74 years. They were randomly
assigned to either the usual-care (control, N = 77, 453) group or the screening with flexible
sigmoidoscopy (intervention, N = 77, 444) group. For the intervention group, subjects were
offered the screening at baseline and 3 or 5 years later. Among them, 187 participants
who left study, dead, diagnosed cancer, or removed organ before the first intervention and
4 participants who have 0 day from trial entry (randomization) to the last follow-up were
ignored. Thus, we only considered 154, 706 individuals in this analysis. The screening
assignment (Z) can be used as an instrument and the treatment variable (D) becomes
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an indicator of screen received at baseline. Table 3.3 presents descriptive statistics for the
baseline characteristics of the participants by the instrumental variable (Z) and the treatment
variable (D). In particular, the main factor of interest is the flexible sigmoidoscopy screening.
We also consider other risk factors such as: sex, age (year), family history of any cancer,
family history of colorectal cancer, colorectal polyps, colon comorbidities, and diabetes.
Table 3.3: Characteristics of the Study Participants
Characteristics Control (Z = 0) Intervention (Z = 1) Not Screened (D = 0) Screened (D = 1)
N = 77449 N = 77257 N = 90056 N = 64650
Number of Participants (%)
Sex
Male 38340 (49.5) 38229 (49.5) 43529 (48.3) 33040 (51.1)
Female 39109 (50.5) 39028 (50.5) 46527 (51.7) 31610 (48.9)
Age§
62.60 (5.37) 62.59 (5.39) 62.65 (5.39) 62.52 (5.33)
Age Level
55-59 yr 25838 (33.4) 25789 (33.4) 29902 (33.2) 21725 (33.6)
60-64 yr 23767 (30.7) 23736 (30.7) 27451 (30.5) 20052 (31.0)
65-69 yr 17473 (22.6) 17402 (22.5) 20352 (22.6) 14523 (22.5)
70-74 yr 10371 (13.4) 10330 (13.4) 12351 (13.7) 8350 (12.9)
Family History of Any Cancer
No 32742 (42.3) 33327 (43.1) 37798 (42.0) 28271 (43.7)
Yes 41305 (53.3) 41971 (54.3) 47137 (52.3) 36139 (55.9)
Unknown 3402 (4.4) 1959 (2.5) 5121 (5.7) 240 (0.4)
Family History of Colorectal Cancer
No 64504 (83.3) 65203 (84.4) 73997 (82.2) 55710 (86.2)
Yes † 7320 (9.5) 7627 (9.9) 8331 (9.3) 6616 (10.2)
Possibly ‡ 1925 (2.5) 2108 (2.7) 2262 (2.5) 1771 (2.7)
Unknown 3700 (4.8) 2319 (3.0) 5466 (6.1) 553 (0.9)
Colorectal Polyps
No 68690 (88.7) 69910 (90.5) 78705 (87.4) 59895 (92.6)
Yes 4947 (6.4) 5185 (6.7) 5739 (6.4) 4393 (6.8)
Unknown 3812 (4.9) 2162 (2.8) 5612 (6.2) 362 (0.6)
Colon Comorbidities
No 72351 (93.4) 73786 (95.5) 82905 (92.1) 63232 (97.8)
Yes 1052 (1.4) 1090 (1.4) 1247 (1.4) 895 (1.4)
Unknown 4046 (5.2) 2381 (3.1) 5904 (6.6) 523 (0.8)
Diabetes
No 68028 (87.8) 69371 (89.8) 77773 (86.4) 59626 (92.2)
Yes 5699 (7.4) 5810 (7.5) 6776 (7.5) 4733 (7.3)
Unknown 3722 (4.8) 2076 (2.7) 5507 (6.1) 291 (0.5)
§ denotes a continuous variable. Mean and standard deviation are reported.
† indicates colorectal-cancer family history in immediate family member.
‡ indicates colorectal-cancer family history in relatives or unclear cancer type.
This trial assumed that at least 85% compliance with screening in the intervention group
and no more than 15% contamination among participants in the usual-care group [62, 63].
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However, note that individuals who are assigned to the usual-care group (Z = 0) do not have
records of treatment by assuming P (D0 = 0|X) = 1. It is a special case referred as a perfect
exclusion of the control group from the treatment [42]. The Assumption 3.2.2 holds trivially
and it implies that only two possible types of compliance strata, compliers and never-takers,
exist. In this case, we have
λ(T |D1 > D0, X,D = 1) = λ(T1|D1 = 1, X, Z = 1) = λ(T1|D = 1, X)
and
λ(T |D1 > D0, X,D = 0) = λ(T0|D1 = 1, X, Z = 0)
= λ(T0|D1 = 1, X, Z = 1) = λ(T0|D = 1, X).
Thus, the proposed estimator describes the effect of the treatment for the treated given X.
The observed time from trial entry (randomization) to death for participants known to
be dead, or to trial exit for participants not known to be dead is given in days. By dividing
365.25, the observed times (days) are transformed into years. The censoring indicator, de-
noted by ∆, is equal to 1 if the individual died only due to colorectal-cancer and 0 otherwise.
Table 3.4: Analysis Results without Covariates
Data N pˆ1 Proposed IV Model Cox Model Cox Model (ITT)
(Subgroup) Estimates (S.E)
Total 154706 0.84 -0.427 (0.100)*** -0.442 (0.088)*** -0.343 (0.083)***
Family History of Any Cancer 83276 0.86 -0.294 (0.125)* -0.237 (0.114)* -0.258 (0.111)*
Family History of Colorectal Cancer 14947 0.87 -0.105 (0.260) -0.010 (0.241) -0.097 (0.239)
Colorectal Polyps 10132 0.85 0.335 (0.369) 0.315 (0.305) 0.288 (0.309)
Colon Comorbidities 2142 0.82 -2.127 (1.060)* -1.772 (1.061)† -2.125 (1.062)*
Diabetes 11509 0.81 -0.603 (0.412) -1.036 (0.311)*** -0.335 (0.253)
p-value: *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05, † ≤ 0.1
Table 3.4 shows the estimation results with different subgroup data sets by risk factors
of colorectal-cancer. Also, three models such as the proposed IV model, the Cox model with
D and the Cox model with Z (ITT) were applied for each data set. For each data set, the
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proportion of compliers p1 is estimated by using the following formula in [41]: p1 = p11−p01,
where p11 is the proportion of participants who would receive treatment (D = 1) if assigned
treatment (Z = 1) and p01 is the proportion of participants who would receive treatment
(D = 1) if assigned treatment (Z = 0). This estimated complier proportion could explain
each others’ distances between three different estimates in Table 3.4. When pˆ1 has a relatively
high value, there is no big difference within the values of hazard ratio by exponentiating the
parameter estimates. For example, the subgroup of individuals who have a colorectal-cancer
family history has the highest pˆ1 value with 0.87 and the corresponding three exponentiated
values are 0.900, 0.990 and 0.908, respectively. In contrast, the subgroup including subjects
who have a diabetes has the lowest pˆ1 value with 0.81. The IV estimate has the middle
value between the estimates of Cox model with D and ITT. In the Cox model, the hazard
ratio is exp(−1.036) = 0.355. A hazard ratio value smaller than 1 says that an increase
in one unit for that particular variable, will decrease the rate of experiencing an event
(end point) throughout the observation period. That is, a screened individual who has
not yet experienced death by colorectal-cancer or not yet censored by a certain time has
the decreased rate of being dead caused by colorectal-cancer at the next point in time by
100% − 35.5% = 64.5% compared to an individual who did not get the screening. Also,
there is a statistically significant association between the screening and mortality caused
by colorectal-cancer with p-value 0.001 which is less than 0.05. In the ITT analysis, the
corresponding hazard ratio is exp(−0.335) = 0.715. Similarly, colorectal-cancer mortality
rate is decreased in the treatment assigned group with 100% − 71.5% = 28.5% compared
to the usual-care assigned group. It is not statistically significant with p-value 0.185 which
is greater than 0.05. The hazard ratio of ITT is nearly two times greater than one of
the Cox model, and the statistical significances are different. The IV estimate −0.603 lies
between the two estimates of the naive models. The hazard ratio of exp(−0.603) = 0.547
corresponds to a decreased rate of colorectal-cancer mortality by 100%−54.7% = 45.3% as D
is altered from the usual-care to the screening within the population subset that has received
52
screening. Also, the results of subset that contains individuals who have colon comorbidities
show difference in parameter estimates. Thus, we will further examine these two subgroups
with considering covariates.
Table 3.5: Analysis Results with Covariates
Colon Comorbidities
Covariate Proposed IV Model Cox Model Cox Model (ITT)
D -2.148 (1.062)* -1.696 (1.061) -2.143 (1.061)*
Gender (Female) 2.013 (1.153)† 1.855 (1.063)† 1.910 (1.064)†
Age 0.224 (0.095)* 0.218 (0.076)** 0.220 (0.074)*
Diabetes
D -0.641 (0.409) -1.076 (0.311)*** -0.361 (0.253)
Gender (Female) -0.846 (0.597) -0.522 (0.270)† -0.475 (0.270)†
Age 0.068 (0.043) 0.097 (0.024)*** 0.096 (0.024)***
Estimates (S.E)
p-value: *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05, † ≤ 0.1
Table 3.5 shows the parameter estimation results with considering two covariates such as
gender and age. Note that the both naive Cox models with four categories of age variable do
not converge in subgroup of colon comorbidities, so the continuous age variable is used. After
accounting for gender and age, there is no statistically significant association between D and
colorectal cancer mortality, but there is a statistically significant association between Z and
colorectal cancer mortality in colon comorbidities subgroup. Conditioning on the covariates,
the average treatment hazard ratio for the treated is exp(−2.148) = 0.117. Consistent with
the ITT analysis results, it is statistically significant. All IV estimates in the subset of colon
comorbidities are similar to the ITT estimates. However, the IV estimates in the subset of
diabetes are different from the others.
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3.5 Discussion
Non-compliance is a common issue in randomized clinical trials or observational studies.
The intention-to-treat analysis ignores non-compliers and the analysis which only focuses on
treatment (D) cannot provide reliable inferences regarding the true effect of the treatment.
To overcome the problem, IV methods can be applied. However, there are limitations in
using IV in recurrent event data analysis. Thus, we suggested an extended Abadie’s IV
method into AG model by using weighting scheme. We could use the similar arguments
with AG model to develop asymptotic properties of the proposed estimators. Note that we
applied this method into PLCO data, which does not include recurrent event data.
However, there are limitations of this method, that is, we could not use full observed data.
For example, the PLCO data have several time variant covariates including the exposure,
and the IV also could be changing by time in longitudinal data. Since we only consider a
binary IV and a binary treatment at baseline in this Chapter, incorporating time variant
covariates and time varying IV into this model will be the future research.
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CHAPTER 4: PARAMETRIC LIKELIHOOD INFERENCE
FOR INTERVAL CENSORED AND LEFT TRUNCATED
COMPETING RISKS DATA
4.1 Introduction
Hudgens et al. [64] developed parametric modeling of the cumulative incidence function
for interval censored competing risks data. We extend their parametric models to addi-
tionally account for left truncation by changing time scale. That is, instead of using the
elapsed time from the study entry to failure time, we applied the time adjusted for age. A
full likelihood estimator is still valid under a mixed case interval censoring model and an
independent inspection process model. However, a naive likelihood method is shown to be
invalid in both settings, while it is not valid only under the independent inspection process
model without considering truncation. This extended parametric method is demonstrated
via comprehensive simulation studies and is applied to data from the Study of Osteoporotic
Fractures to obtain bone mineral density (BMD) testing interval by age as a time scale.
In this chapter, we develop parametric estimation methods for competing risks survival
data subject to interval censoring and left truncation. These methods are motivated by
clinical practice guidelines for bone mineral density (BMD) screening to identify and treat
osteoporosis (very low bone density) for fracture prevention in postmenopausal women. Clin-
ical practice guidelines agree that women aged 65 and older should receive BMD testing to
detect and treat osteoporosis [65–67]. However, no standard BMD screening interval has
been recommended. To guide decisions about the interval of BMD tests for women aged
65 and older, Gourlay et al. [68] conducted a competing risk analysis of BMD screening
intervals using data from the Study of Osteoporotic Fractures (SOF) observational study of
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BMD and fractures in women aged 65 and older at study entry. For four different risk strata
(Normal BMD, Mild osteopenia, Moderate osteopenia, Advanced osteopenia) reflecting an
increasing fracture risk correlating with baseline BMD testing scores, they provided cumula-
tive incidence curves of osteoporosis by applying Hudgens’ parametric method [64] with the
standard approach using the elapsed time from the baseline to the occurrence of the event as
the time scale. Interval censoring arose, because BMD was measured intermittently. Thus,
the time to osteoporosis was not directly observed, but was only known up to some intervals.
Incident hip and clinical vertebral fractures and pharmacologic treatment were considered
to be competing risks, because individuals who have hip or clinical vertebral fractures are
always treated regardless of their BMD level, and treated individuals no longer need BMD
risk stratification.
Unlike the work done in the previous study, we seek to estimate the cumulative incidence
curves of osteoporosis with age as a time scale instead of using time in the study. This
creates a left truncation issue because subjects entered into the study at different ages and
the necessary BMD measurements were not initiated until 2 years after baseline enrollment.
For example, women entering the study at age 65 who had the event (osteoporosis) before
age 67 (when their BMD measurements began) were not considered as incident osteoporosis
cases. That is, left truncation occurs when the subjects have been at risk before beginning
BMD measurements in this study (or before study entry in other cases). Lamarca et al.
[69] indicated that the usage of age as time is more appropriate for survival analysis of the
elderly population where the goal is to describe the risk factors that modify the hazard of
the failure after a specific age, 65 years in SOF data. Cain et al. [70] also supported that
bias can be increased and that standard errors can be underestimated by ignoring delayed
entries. Thus, bias can be reduced when analyses account for left truncation, although the
results are unstable when there are higher levels of truncation.
It is a common interest to estimate cumulative incidence function (CIF), which is the
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probability of a specific event occurrence by time t, in the presence of other competing
events. Hudgens et al. [71] computationally derived a nonparametric maximum likelihood
estimator (NPMLE) of the CIFs for competing risks data subject to interval censoring and
truncation by generalizing Turnbull’s estimator [72]. The NPMLE and the naive estimator
of the CIF for current status data had been studied by Jewell et al. [73] and Groeneboom
et al. [74, 75]. Li and Fine [76] applied kernel smoothing to estimate the NPMLE of the
CIF and the cause-specific hazard function (CSHF) in current status data with competing
risks. Since the nonparametric estimation require intense computation [64, 74], parametric
models can be preferred in this case.
Based on Jeong and Fine [77] which suggested parametric estimation method of the CIF
for right censored competing risks data, Hudgens et al. [64] extended the parametric models
for allowing interval censoring with considering both full maximum likelihood estimators
(MLEs) and naive estimators. In this Chapter 4, we conduct competing risks analysis addi-
tionally accounting for left truncation by extending the parametric estimation method from
Hudgens et al. [64]. The remaining sections are organized as follows. We begin by intro-
ducing notations and the proposed parametric modeling, and its estimation and asymptotic
properties are given in Section 4.2. In Section 4.3, we present simulation studies conducted
to examine the feasibility of the extended method, and results of the SOF data analysis are
reported in Section 4.4.
4.2 Inference
4.2.1 Notations and Parametric Modelling
Let K ∈ {1, . . . , nK} denote the cause of failure. An individual can only experience one
of nK distinct mutually exclusive competing causes. Let T denote a continuous random
variable representing the time of failure, which is only known up to some interval. The CIF
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for type k failure is defined as Fk(t) = Pr[T ≤ t,K = k], i.e., the cumulative probability
of type k failure in the presence of other competing events. It is also expressed in terms of
CSHF, such that Fk(t) =
∫ t
0
S(u)λ∗k(u), where S(t) = exp{−
∫ t
0
∑nK
k=1 λ
∗
k(u)du} is the overall
survival function and λk(t) = limdt→0{Pr(t ≤ T < t + dt,K = k|t ≤ T )/dt} is known to be
as CSHF of the type k.
To overcome complication due to interval censoring, the direct parameterization of the
CIF without covariates by Jeong and Fine [77] is applied. Also, it gives natural interpretation
concerning the probability of an event of interest. A parametric model Fk(t; Θk) is separately
specified for each CIF with distinct Θk for each k. We also adopt the Gompertz model in
Jeong and Fine [77], which is defined by
Fk(t; Θk) = 1− exp[βk{1− exp(αkt)}/αk] (4.2.1)
with Θk = (αk, βk) where αk < 0 and βk > 0 so that the function (4.2.1) is an improper
distribution function. That is, the CIF satisfies limt→∞ Fk(t) < 1 when nK > 1 and the
probability of experiencing each cause has positive value. The corresponding hazard function
is given by
λk(t) = βk exp(αkt). (4.2.2)
This model satisfies
0 < Fk(t; Θk) < 1 for all t > 0 and k = 1, . . . , nK , and (4.2.3)
Fk(t; Θk) is monotone increasing function of t for k = 1, . . . , nK . (4.2.4)
Similar to Hudgens et al. [64], we consider two observation processes such as the mixed
case and independent inspection process (IIP) models by revisiting notations. Additionally,
we consider that the T is left truncated at V0 with a time origin that is the same for all failure
types. If the time origin is smaller than the minimum value of V0, then the estimated CIF is
used for extrapolation i.e. predicting the response to an input which lies outside of the range
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of the values of the observed intervals used to fit the model. Conversely, when one is bigger,
we will assume that there are no event between the corresponding V0’s and the time origin
by ignoring the periods. The former will be considered and then we need to consider the
conditional distribution of T given T > V0. Let V = (V0, V1, . . . , VM) be the vector of ordered
observation times where M is the random number of observation times for an individual,
V0 ≥ 0 and VM+1 =∞ such that Vl−1 < Vl for l = 1, . . . ,M + 1. Define ∆kl = 1(Vl−1 < T ≤
Vl, K = k) for k = 1, . . . , nK and l = 1, . . . ,M . That is, ∆kl equals 1 if a subject has an event
of type k during (Vl−1, Vl] and 0 otherwise. Let ∆M+1 = 1−
∑nK
k=1
∑M
l=1 ∆kl. When ∆M+1 = 1,
the event type is unknown and right censored. Instead of observing (T,K) directly, we
observe copies of Y = (M,V,∆) where ∆ = (∆11, . . . ,∆1M ,∆21, . . . ,∆nKM ,∆M+1). Under
the mixed case interval censoring model, (M,V ) |= (T,K) is assumed. It implies that the
observation process is determined independently of the failure time and the cause of failure.
For l = 1, 2, . . ., define the history of observation times and failure information by
Hl = (V1, . . . , Vl−1,∆11, . . . ,∆nK1, . . . ,∆1,l−1, . . . ,∆nK ,l−1|V0), where H1 = V0. Under the
IIP model, it is assumed Vl |= (T,K)|Hl implying that the next observation times is inde-
pendent with the failure time and cause given the history of observation times and failure
information. That is, the IIP stops if a failure is detected, such that ∆jl = 0 for all l < M
and j ∈ {1, . . . , nK}. Thus, the IIP model is more appropriate when future observation
times depend on the history of the observed data [78].
4.2.2 Estimation and Asymptotic Properties
Let Y1, . . . , Yn be a random sample of n independent and identically distributed copies
of Y . Therefore, the corresponding log likelihood functions for Y1, . . . , Yn under the mixed
case interval censoring model and the IIP model are following
logL(Θ) =
n∑
i=1
log `(Yi; Θ), (4.2.5)
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where Θ is the vector consisting of elements of Θ1 ∪ . . . ∪ΘnK and
`(Yi; Θ) =
nK∏
k=1
M∏
l=1
{
Fk(vl; Θk)− Fk(vl−1; Θk)
1−∑nKk=1 Fk(v0; Θk)
}∆kl {1−∑nKk=1 Fk(vm; Θk)
1−∑nKk=1 Fk(v0; Θk)
}∆M+1
. (4.2.6)
The full likelihood estimator of Θ, Θˆ, is defined by the value that maximizes (4.2.5) with
the assumptions 4.2.3 and 4.2.4. They cannot be separately estimated by the failure type k.
Under certain regularity conditions, the maximum likelihood estimates of Θ have consistency
and asymptotic normality with mean Θ and covariance matrix ΣΘ. By taking the negative
second derivatives of the log likelihood function (4.2.5) with respect to Θ, the observed
information matrices can be computed and inverted to estimate the ΣΘ. The estimated
Fk(t; Θˆk) is also approximately Normal distribution with mean Fk(t; Θk) and covariance
matrix Σ(t) by using the multivariate delta method. The Σ(t) can be estimated by
v̂ar{Fk(t; Θˆk)} = Σˆ(t) =
(
∂Fk(t; Θk)
∂Θk
)
ΣˆΘˆ
(
∂Fk(t; Θk)
∂Θk
)′∣∣∣∣
Θ=Θˆ
(4.2.7)
, for k = 1, . . . , nK . The ΣˆΘˆ is the inverse of the observed Fisher information, evaluated at
the parameter estimates Θˆ. A pointwise (1 − α)% confidence interval (CI) for Fk(t; Θˆk) at
time t is given by
Fk(t; Θˆk)± z1−2/α
√
Σˆ(t), (4.2.8)
where zq is the q quantile of the standard normal distribution. Note that the estimation is
only valid on the support of the observation time. To test differences between the probability
of a particular failure type by time t between two subgroups, i.e., the null hypothesis is
H0 : F
1
k (t; Θ
1
k) = F
2
k (t; Θ
2
k), where F
g
k (t; Θ
g
k) denote the CIF for a failure of type k and Θ
g
k
are corresponding parameter in subgroup g = 1, 2. The Wald type test statistics is following:
F 1k (t; Θˆ
1
k)− F 2k (t; Θˆ2k)/
√
v̂ar{F 1k (t; Θˆ1k)}+ v̂ar{F 2k (t; Θˆ2k)} (4.2.9)
which follows a standard Normal distribution under the null hypothesis.
Note that in addition to this full likelihood method, Hudgens et al. [64] considered a
naive likelihood for estimating the CIF by using a reduced data. Since the naive estimator
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enables separate estimation of models for each cause, unlike the MLEs where all models
are fitted simultaneously. Thus, it is computationally easier to estimate than the MLEs.
However, we need to estimate all Θk’s for k = 1, . . . , nK to calculate Pr[T > v0]. Therefore,
the naive likelihood method cannot be applied.
4.3 Simulation Studies
We adopted simulation settings from Hudgens et al. [64]. There are two causes of failure,
i.e., nK = 2. The event type k and the failure time T given k are generated by using
Pr[K = k; Θk] = 1− exp(βk/αk) and Fk(t; Θk) = Pr[T ≤ t|K = k; Θk]Pr[K = k; Θk], where
Θk = (αk, βk) for k = 1, 2. The left truncation time V0 is randomly drawn from a uniform
distribution between 0 and u. Two different values 5 and 10 for u have different truncation
rates 0.16 and 0.29, respectively. The truncation rate for each iteration is obtained by taking
an average of cases when the event times are less than the truncation time point, V0, and then
take average of the truncation rates over the iterations. The following observation times V1 <
. . . < V7 are randomly generated with V1 = V0 + Unif (3, 5), V2 = V0 + Unif (7, 9), . . . , V6 =
V0 + Unif (23, 25), and V7 = V0 + 28. We start with an vector, (−0.01, 0.01,−0.01, 0.01), for
the initial values of (α1, β1, α2, β2). We consider sample size n = 500, 1000, 2000 and each
scenario is replicated 1, 000 times.
We report bias (BIAS), empirical standard deviation (ESD), defined by the sample stan-
dard deviation of the replicated estimates, average of the replicated standard deviation es-
timates (TSD), and empirical coverage probability (CP) at a 0.95 nominal level in Table
4.1. The columns of LT(5) and LT(10) indicate the results of accounting for two different
left truncation proportions. To check appealing features by considering left truncation, the
results without adjusting left truncation are also presented in last three columns denoted by
FL. All estimators are approximately unbiased. The estimates with considering left trun-
cation have biases closer to 0 than the ones without considering left truncation, and the
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Table 4.1: Simulation Results with (α1, β1, α2, β2) = (−0.058, 0.0093,−0.035, 0.067)
LT(5) LT(10) FL
n 500 1000 2000 500 1000 2000 500 1000 2000
α1 BIAS 0.008 -0.060 -0.020 0.004 -0.068 -0.020 -0.032 -0.096 -0.046
ESD 1.839 1.318 0.940 1.840 1.283 0.954 1.504 1.038 0.750
TSD 1.852 1.304 0.92 1.890 1.331 0.939 1.607 1.132 0.798
CP 0.949 0.955 0.951 0.959 0.968 0.941 0.962 0.977 0.965
β1 BIAS 0.019 0.018 0.006 0.027 0.024 0.008 0.012 0.017 0.007
ESD 0.251 0.180 0.128 0.291 0.203 0.152 0.197 0.137 0.099
TSD 0.253 0.179 0.126 0.297 0.21 0.147 0.198 0.141 0.099
CP 0.939 0.949 0.938 0.941 0.955 0.935 0.946 0.970 0.941
α2 BIAS -0.002 -0.007 -0.010 -0.008 0.018 0.005 0.007 0.004 -0.003
ESD 0.780 0.559 0.414 0.801 0.582 0.419 0.691 0.469 0.332
TSD 0.800 0.566 0.400 0.825 0.582 0.412 0.692 0.489 0.346
CP 0.959 0.949 0.949 0.956 0.951 0.946 0.963 0.955 0.964
β2 BIAS 0.014 0.015 0.021 0.027 -0.001 0.008 -0.001 0.008 0.009
ESD 0.739 0.528 0.388 0.873 0.626 0.445 0.607 0.420 0.300
TSD 0.744 0.526 0.372 0.878 0.618 0.438 0.577 0.410 0.289
CP 0.951 0.950 0.941 0.940 0.943 0.946 0.946 0.950 0.947
BIAS (×102), ESD (×102), TSD (×102)
bias is decreasing as the fraction of truncation is getting lower. In addition, standard er-
rors are underestimated when left truncation is ignored. These findings are consistent with
Cain et al. [70] as we mentioned in Section 4.1. The variance estimates using the observed
information are similar to the corresponding empirical variances of the estimators, so the
empirical coverage probabilities are nearly reached up to the nominal level 95.
4.4 Application: The Study of Osteoporotic Fractures
For clinical applications, bone mineral density (BMD) measurements are converted to
T-scores, i.e.
BMD of participant mean BMD of young reference population
SD of BMD of a young female reference population
.
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A BMD test can identify osteoporosis, the most important marker of fracture risk which is
defined as lowest BMD T-score ≤ −2.50 at one or more of three anatomical sites in the lower
spine and hip [79]. T-scores > −2.50 represent lesser degrees of fracture risk, i.e., T-score
−1.00 and higher at all hip and spine sites is considered normal or healthy, and lowest T-
score between −1.01 and −2.49 indicates osteopenia. The BMD testing interval was defined
as the estimated time during which osteoporosis developed in 10% of women to make the
transition to osteoporosis from normal BMD or osteopenia at baseline before having a hip
or clinical vertebral fracture.
The BMD testing to screen for osteoporosis is recommended for women 65 years of age or
older. To determine the BMD testing interval via age scale, we studied 4957 women, aged 67
years or older and recruited between 1986 and 1988, who did not have osteoporosis at baseline
and who were followed prospectively for up to 15 years. The follow-up period included study
examinations at year 2 (1989-1990), year 6 (1992-1994), year 8 (1995-1996), year 10 (1997-
1999), and year 16 (2002-2004), which represented the time period during which BMD and
fracture were followed concurrently. Thus, interval censoring occurs since a random variable
of interest, i.e., time to osteoporosis, is known only to lie within an interval between BMD
examinations at intermittent study visits instead of being observed exactly. Also, our goal
is to estimate the cumulative incidence curves of osteoporosis with age as time scale, which
accompanies left truncation. Because individuals who have already experienced osteoporosis
or having a hip or clinical vertebral fracture were not included in the study and they entered
into the study at different ages. Therefore, we need to account for the probability that the
osteoporosis has not been occurred before the entry age years. Thus, age minus 65 was taken
as the time scale. Similar to the Gourlay et al. [68], the analysis included the 513 women
who made the transition from normal BMD to osteopenia and had at least one subsequent
examination with BMD recorded. In other words, total 4957 + 513 = 5470 records are used
by assuming independence. We consider two failure types (nK = 2) such as osteoporosis and
others including incident hip or clinical vertebral fractures and the first reported use of a
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Food and Drug Administration (FDA) approved agent for the treatment of osteoporosis.
Table 4.2: Characteristics of the Study Participants
Failure Types
Total No Event Osteoporosis Others
Characteristics N = 5470 (100) N = 3704 (67.7) N = 1224 (22.4) N = 542 (9.9)
Age†
72.67 (4.38) 72.64 (4.39) 73.12 (4.41) 71.89 (4.07)
Age Level
67-74 yr 3838 (70.2) 2610 (68.0) 821 (21.4) 407 (10.6)
≥75 yr 1632 (29.8) 1094 (67.0) 403 (24.7) 135 (8.3)
T-score
≥-1, normal 1255 (22.9) 1171 (93.3) 10 (0.8) 74 (5.9)
(-1.50, -1), mild osteopenia 1386 (25.3) 1195 (86.2) 64 (4.6) 127 (9.2)
(-2, -1.50], moderate osteopenia 1478 (27.0) 972 (65.8) 309 (20.9) 197 (13.3)
≤-2, advanced osteopenia 1351 (24.7) 366 (27.1) 841 (62.3) 144 (10.7)
BMI (4)
<18.5, underweight 31 (0.6) 14 (45.2) 15 (48.4) 2 (6.5)
[18.5-25), normal 1940 (35.6) 1149 (59.2) 572 (29.5) 219 (11.3)
[25-30), overweight 2164 (39.7) 1493 (69.0) 451 (20.8) 220 (10.2)
≥30, obese 1310 (24.1) 1029 (78.5) 182 (13.9) 99 (7.6)
BMI (2)
<30 4160 (76.1) 2675 (64.3) 1042 (25.0) 443 (10.6)
≥30 1310 (23.9) 1029 (78.5) 182 (13.9) 99 (7.6)
Family History of Hip Fracture
No 4845 (88.6) 3301 (68.1) 1065 (22.0) 479 (9.9)
Yes 625 (11.4) 403 (64.5) 159 (25.4) 63 (10.1)
Number of Participants (%)
† denotes a continuous variable. Mean and standard deviation are reported.
Body mass index (BMI)= mass(kg)
height2(m2)
= mass(lb)
height2(in2)
× 703
Table 4.2 presents descriptive statistics of several clinical risk factors’ characteristics at
the baseline by the failure types. Note that age cannot be used as a covariate. The age range
at baseline is from 67 to 91. The corresponding largest VM is 99, so the range of observation
time is [67, 99] in age scale. We applied the Gompertz model with two parameters. Since the
Gompertz model is suitable when there is a subset of the population can never experience
the event of interest.
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Figure 4.1 shows the estimates of the CIFs (solid lines) and the 95% CIs (dotted lines)
for the two parameters Gompertz models accounting for BMI (2) and family history of
hip fracture at baseline, separately. The grey horizontal dashed line represents the 10%
threshold for the transition to osteoporosis. This line intersects each cumulative incidence
curve and the corresponding values of x axis would be the estimated testing intervals in age
scale between 65 and 99, respectively. The times in age scale for 10% of women without
osteoporosis to make the transition to osteoporosis decreased with lower BMI or with family
history of hip fracture. The estimates are 68.57 years for women whose BMI less than 30 and
71.26 years for those with obese. By contrast, the estimates for women with family history
and for those without family history are very similar with 68.47 and 69.02, respectively. The
grey vertical dashed line represents the minimum observed age in this study, 67 years.
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Figure 4.1: Estimated CIFs and CIs for Osteoporosis by BMI (2) and Family History
Then, the Figure 4.2 shows the CIF estimates by considering combination with these two
BMI and family history and by adjusting with four categories of BMI instead of two. The
estimated ages for 10% of subjects having the transition to osteoporosis are 68.23, 68.61,
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Figure 4.2: Estimated CIFs for Osteoporosis by Combining with BMI (2) and Family History
and by BMI (4)
Table 4.3: Estimates of the Osteoporosis Development in 10% of Participants
Subgroup N Age Estimates 95% CI
BMI < 30 & Family History=Yes 476 68.23 0.10 (0.063, 0.136)
BMI < 30 & Family History=No 3684 68.61 0.10 (0.094, 0.106)
BMI ≥ 30 & Family History=Yes 149 69.80 0.10 (0.061, 0.139)
BMI ≥ 30 & Family History=No 1161 71.53 0.10 (0.069, 0.131)
BMI < 18.5 31 65.88 0.10 (0.000, 0.217)
18.5 ≤ BMI < 25 1940 67.76 0.10 (0.082, 0.118)
25 ≤ BMI < 30 2164 69.36 0.10 (0.091, 0.109)
BMI ≥ 30 1310 71.26 0.10 (0.070, 0.130)
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69.80 and 71.53 in the left and 65.88, 67.76, 69.36 and 71.26 in the right with the same
order of the legend. The corresponding CIF estimates and CIs are reported in Table 4.3.
Note that the number of women who have less than 18.5 BMI is only 31, so it has a wide
95% CI. However, we still can check that the BMI gives more noticeable separation between
subgroups than the family history. We might conclude that the BMI is a key variable to
explain occurrence of osteoporosis.
Existing analyses of osteoporosis risk assessment tools suggest that our findings are robust
and clinically relevant. Ravn et al. [80] concluded that thinness, defined by low percentage
of body fat, low BMI, or low body weight, is an risk factor for low bone mass and fast bone
loss in postmenopausal women. Also, DeLaet et al.’s meta-analysis of BMI as a predictor
of fracture concluded that low BMI confers a risk of substantial importance for all fractures
that is largely independent of age and sex, but dependent on BMD [81]. Systematic reviews
of osteoporosis risk assessment tools have demonstrated that simple risk tools perform as
well as complicated risk tools to identify postmenopausal women aged 50 and older with
osteoporosis [82, 83]. For example, the Osteoporosis Self-Assessment Tool based on age and
body weight alone performed as well or better (as demonstrated by the area under the ROC
curve) than risk tools including as many as 6 clinical risk factors [84–86]. This is consistent
with our finding of improved osteoporosis risk stratification (more distinct separation of
cumulative incidence curves for osteoporosis) by using BMI rather than BMI combined with
family history of fracture for the baseline predictor.
4.5 Conclusion
The goal of this Chapter is to estimate the cumulative incidence functions of osteoporo-
sis with age as time scale instead of gap time from the beginning of the study to the event.
Thus, left truncation has been considered with interval censoring in competing risk setting
by extending Hudgens et al.’s parametric estimation method [64]. The numerical studies sug-
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gested that the proposed estimation performs well when the parametric models are correctly
specified, and also bias can be reduced with a relatively lower truncation rate. Additionally,
because left truncation of the outcome measure at study entry is common in the data sets
used for analyses of many risk assessment tools (not just for osteoporosis), we conclude that
our left truncation methods have potential for expanded use in clinical studies of screening
tests, especially those based on continuous measures/scores.
However, as we mentioned in Section 4.2, we could not apply the naive estimation method,
which can separately estimate for each event type by treating other events as independent
censoring events, since we still need to estimate all other parameters for different causes to
calculate the truncation probability in denominator. Thus, it could be a future study to
utilize the naive likelihood method.
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CHAPTER 5: SUMMARY AND FUTURE STUDIES
In this dissertation we have studied about recurrent event data within different circum-
stances. We focused on recurrence of the same type of events in Chapter 2 and Chapter 3,
and we slightly changed it to the competing risks setting allowing different types of events
so that the occurrence of event caused by one type may prohibit to observe the other type
of events in Chapter 4.
In Chapter 2, we proposed the self-triggering Cox (STC) model for recurrent event data,
and compared with the existing methods. Also, to address the non-identifiability of the
STC model under the null of no triggering effect, the Bonferroni correction procedure was
suggested to adjust for multiple testing at given some values for the non-identifiable param-
eter. The simulation studies indicate that the adjustment appears to be rather conservative
and a test at a single values may provide greater power than the multiple testing approach.
In addition, we demonstrated that the extended Cox model may give significant gains in
prediction of future events compared to available models.
In Chapter 3, we considered non-compliance issue within recurrent time-to event data by
using instrumental variable. Because the intention-to-treat analysis ignores non-compliers
and the analysis which only focuses on treatment cannot provide reliable inferences regarding
the true effect of the treatment. We suggested to extend Abadie’s IV method into Anderson-
Gill (AG) model and additionally into Cox model. We showed that the similar arguments
with AG model can be used to develop asymptotic properties of the proposed estimators
by using weighting scheme. Through PLCO data analysis, we demonstrated the proposed
method with Cox proportional hazards model instead of AG model.
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In Chapter 4, to estimate the cumulative incidence functions by accommodating left
truncation and interval censoring within competing risks data setting, we extended Hudgens
et al.’s parametric estimation method. The numerical studies suggested that the bias reduced
compared to the one from the estimation without considering left truncation. In addition, we
applied the extended parametric modeling for analyzing data from the study of osteoporotic
fractures.
There are several future researches that would be invoked by the presented works in
this dissertation. Firstly, we can generalize the STC model with using different intensity
functions, or we could incorporate the number of lag as an additional parameter in the
current model. Also, to deal with non-identifiability under the null, more rigorous testing
method would be required. Secondly, the suggested IV method has not been verified with
time varying covariates and time varying IV, it could be another candidate for the future
study. Additionally, we still need to demonstrate the method with AG model by applying it
into the real data analysis. Lastly, we could not apply the naive estimators by adding left
truncation. Thus, we can propose pairwise likelihood method to utilize the naive likelihood
method which makes estimation procedure simpler by allowing separate estimation for each
failure type.
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APPENDIX I: ADDITIONAL TABLES FOR CHAPTER 2
Table 5.1, 5.2 and 5.3 show the Anderson-Gill (AG) model estimation results when θ1 =
(β1c, β2c)
′ = (0.5, 1.0)′ and θ2 = θ3 = (β1o, β2o)′ = (0.3, 0.5)′ with different p1 intervals,
respectively, and Table 5.4 shows the simulation results with the same setting except β2c to
test H0 : β2c = 0.
We additionally report Table 5.5, which shows the Cox model estimation results when
θ1 = (β1c, β2c)
′ = (0.5, 1.0)′ and θ2 = θ3 = (β1o, β2o)′ = (0.3, 0.5)′ with different p1 intervals,
respectively.
Table 5.1: Simulation Results (AG model) with p1 = [.41, .49]
Prob.Complier (p1) [.41, .49]
Known weight Unknown weight AG model
N 500 1000 2000 500 1000 2000 500 1000 2000
MEAN 0.517 0.503 0.500 0.517 0.500 0.500 0.459 0.457 0.460
MED 0.502 0.498 0.496 0.496 0.499 0.498 0.458 0.456 0.461
X(β1c) ESD 0.195 0.131 0.089 0.193 0.134 0.088 0.067 0.046 0.033
TSD 0.223 0.136 0.095 0.223 0.144 0.091 0.062 0.044 0.031
CP 97.7 97.3 96.1 98.3 97.5 95.9 86.7 82.2 72.3
MEAN 1.020 1.014 1.004 1.007 1.009 1.002 0.629 0.627 0.627
MED 1.020 1.014 1.003 1.008 1.009 1.000 0.625 0.628 0.627
D(β2c) ESD 0.157 0.115 0.074 0.152 0.110 0.070 0.066 0.049 0.033
TSD 0.200 0.115 0.077 0.170 0.112 0.074 0.062 0.044 0.031
CP 97.3 95.9 95.9 96.5 95.0 95.3 0 0 0
Outlier/No convergence 29 10 2 25 12 5 0 0 0
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Table 5.2: Simulation Results (AG model) with p1 = [.51, .67]
Prob.Complier (p1) [.51, .67]
Known weight Unknown weight AG model
N 500 1000 2000 500 1000 2000 500 1000 2000
MEAN 0.500 0.505 0.500 0.502 0.504 0.501 0.516 0.577 0.548
MED 0.491 0.501 0.500 0.491 0.502 0.498 0.514 0.576 0.550
X(β1c) ESD 0.147 0.099 0.065 0.156 0.100 0.064 0.066 0.046 0.044
TSD 0.154 0.099 0.068 0.159 0.096 0.068 0.062 0.043 0.031
CP 97.2 94.6 95.6 97.3 95.6 95.7 92.0 57.4 57.7
MEAN 1.008 1.004 1.003 1.006 1.001 1.001 0.680 0.712 0.695
MED 1.009 1.000 1.003 1.006 0.996 1.001 0.681 0.712 0.695
D(β2c) ESD 0.111 0.077 0.053 0.106 0.075 0.051 0.064 0.044 0.035
TSD 0.121 0.079 0.054 0.113 0.073 0.053 0.060 0.042 0.030
CP 96.4 95.5 94.3 96.7 94.8 95.4 0.3 0 0
Outlier/No convergence 4 2 4 7 3 2 0 0 0
Table 5.3: Simulation Results (AG model) with p1 = [.63, .84]
Prob.Complier (p1) [.63, .84]
Known weight Unknown weight AG model
N 500 1000 2000 500 1000 2000 500 1000 2000
MEAN 0.503 0.500 0.502 0.504 0.500 0.502 0.567 0.567 0.569
MED 0.499 0.498 0.502 0.499 0.497 0.503 0.566 0.565 0.568
X(β1c) ESD 0.126 0.081 0.059 0.117 0.081 0.059 0.069 0.048 0.032
TSD 0.124 0.080 0.056 0.120 0.081 0.056 0.063 0.044 0.031
CP 96.3 95.8 94.2 95.7 95.5 94.1 79.6 66.1 40.6
MEAN 1.002 1.000 0.999 1.001 0.998 0.999 0.884 0.881 0.882
MED 1.001 1.001 1.000 1.000 1.001 1.001 0.885 0.882 0.883
D(β2c) ESD 0.086 0.057 0.041 0.084 0.056 0.041 0.065 0.045 0.032
TSD 0.086 0.059 0.041 0.086 0.059 0.041 0.060 0.042 0.030
CP 95.7 96.2 95.2 95.7 96.3 94.6 50.9 21.9 3.3
Outlier/No convergence 3 0 0 3 1 0 0 0 0
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Table 5.4: Simulation Results for Hypothesis Testing H0 : β2c = 0 with (β1c, β1o, β2o) =
(0.5, 0.3, 0.5)
β2c = 0 β2c = 0.1 β2c = 0.2
N 500 1000 2000 500 1000 2000 500 1000 2000
Prob.Complier (p1) Method Type I error Power Power
[.41, .49] Known weight 2.29 3.83 4.54 7.56 10.91 21.45 17.79 35.47 60.80
Unknown weight 2.97 4.04 4.41 8.64 12.46 20.90 20.95 37.51 63.95
AG model 100 100 100 100 100 100 100 100 100
[.51, .67] Known weight 3.03 3.90 4.20 12.02 18.33 33.80 35.05 58.33 87.99
Unknown weight 2.63 4.30 4.70 12.69 18.88 32.83 36.71 59.62 86.86
AG model 99.2 100 100 99.7 100 100 99.9 100 100
[.63, .84] Known weight 5.73 3.32 5.20 15.68 30.58 47.30 50.10 81.80 97.90
Unknown weight 6.14 3.31 5.32 16.98 30.95 47.55 51.92 81.30 98.50
AG model 61.3 88.9 99.5 89.1 99.1 100 98.1 100 100
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Table 5.5: Simulation Results (Cox model) with (β1c, β1o, β2c, β2o) = (0.5, 0.3, 1.0, 0.5)
Prob.Complier (p1) [.41, .49]
N 500 1000 2000 4000 8000
MEAN 0.530 0.538 0.512 0.509 0.505
MED 0.519 0.514 0.500 0.501 0.507
X(β1c) ESD 0.440 0.348 0.241 0.131 0.088
TSD 1.054 0.488 0.304 0.272 0.129
CP 96.0 96.7 96.3 96.0 95.8
MEAN 1.102 1.099 1.057 1.029 1.012
MED 0.977 1.015 1.003 1.017 1.000
D(β2c) ESD 0.595 0.462 0.335 0.197 0.145
TSD 0.826 0.523 0.312 0.235 0.199
CP 91.4 93.3 94.6 95.5 95.5
Outlier/No convergence 223 133 87 50 28
Prob.Complier (p1) [.51, .67]
MEAN 0.516 0.519 0.505 0.498 0.501
MED 0.506 0.511 0.507 0.499 0.501
X(β1c) ESD 0.289 0.217 0.123 0.086 0.057
TSD 0.430 0.281 0.157 0.099 0.078
CP 96.7 97.0 96.5 96.3 94.9
MEAN 1.092 1.050 1.014 1.002 0.999
MED 1.022 1.011 0.996 0.997 0.999
D(β2c) ESD 0.438 0.292 0.156 0.100 0.070
TSD 0.504 0.287 0.160 0.107 0.080
CP 93.4 95.8 96.6 94.6 95.3
Outlier/No convergence 142 67 29 20 10
Prob.Complier (p1) [.63, .84]
MEAN 0.542 0.512 0.504 0.499 0.501
MED 0.540 0.506 0.501 0.499 0.500
X(β1c) ESD 0.262 0.172 0.105 0.072 0.049
TSD 0.460 0.190 0.152 0.081 0.061
CP 95.8 96.1 95.7 95.9 95.2
MEAN 1.028 1.007 1.001 1.003 0.999
MED 1.017 1.012 0.998 1.003 1.000
D(β2c) ESD 0.227 0.134 0.092 0.067 0.045
TSD 0.425 0.139 0.105 0.066 0.051
CP 95.6 95.4 95.4 94.4 94.4
Outlier/No convergence 76 33 29 15 6
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APPENDIX II: PROOFS FOR CHAPTER 4
Appendix A: Likelihood
a: The Mixed Case Interval Censoring Model
The probability of the observed data Y = (M,V,∆) for ∆kl = 1 equals to
Pr[M = m,V = v,∆kl = 1|T > v0]
= Pr[M = m,V = v, T ∈ (Vl−1, Vl], K = k|T > v0],
=
Pr[T ∈ (Vl−1, Vl], T > v0, K = k,M = m,V = v]
Pr[T > v0]
=
Pr[T ∈ (vl−1, vl], K = k|M = m,V = v]Pr[M = m,V = v]
Pr[T > v0]
, since (M,V ) |= (T,K)
=
Pr[T ∈ (vl−1, vl], K = k]Pr[M = m,V = v]
Pr[T > v0]
.
Since the Pr[M = m,V = v] does not involve with parameters from Θ, the likelihood is only
related to Pr[T ∈ (vl−1, vl], T > v0, K = k] = Fk(vl; Θk) − Fk(vl−1; Θk) and Pr[T > v0] =
1−∑nKk=1 Fk(v0; Θk).
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Similarly, for right censored observations, i.e., ∆M+1 = 1, we have
Pr[M = m,V = v,∆M+1 = 1|T > v0]
= Pr[M = m,V = v, T > VM |T > v0],
=
Pr[T > VM , T > v0,M = m,V = v]
Pr[T > v0]
,
=
Pr[T > vM |M = m,V = v]Pr[M = m,V = v]
Pr[T > v0]
, since (M,V ) |= (T,K)
=
Pr[T > vM ]Pr[M = m,V = v]
Pr[T > v0]
.
The corresponding likelihood equals to Pr[T>vM ]
Pr[T>v0]
. Therefore,
logL(Θ) =
n∑
i=1
log `(Yi; Θ),
where
`(Yi; Θ) =
nK∏
k=1
M∏
l=1
{
Fk(vl; Θk)− Fk(vl−1; Θk)
1−∑nKk=1 Fk(v0; Θk)
}∆kl {1−∑nKk=1 Fk(vm; Θk)
1−∑nKk=1 Fk(v0; Θk)
}∆M+1
.
b: The IIP Model
The probability of the observed data (M,V,∆) for ∆kM = 1 equals to the following
m−1∏
l=1
1
Pr[T > v0]
× Pr[Vl = vl|Hl = hl]Pr[∆1l = . . . = ∆nK l = 0, T > v0|Hl = hl, Vl = vl]
× Pr[VM = vm|HM = hm]Pr[∆kM = 1, T > v0|HM = hm, VM = vm],
∼
m−1∏
l=1
1
Pr[T > v0]
Pr[∆1l = . . . = ∆nK l = 0, T > v0|Hl = hl, Vl = vl]
× Pr[∆kM = 1, T > v0|HM = hm, VM = vm].
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For ∆kl = 1, the corresponding probability is
Pr[∆kl = 1, T > v0|Hl = hl, Vl = vl]
= Pr[vl−1 < T ≤ vl, K = k, T > v0|Hl = hl, Vl = vl] , since Vl |= (T,K)|Hl
= Pr[vl−1 < T ≤ vl, K = k, T > v0|Hl = hl]
= Pr[vl−1 < T ≤ vl, K = k, T > v0|Hl−1 = hl−1, Vl−1 = vl−1,∆1,l−1 = . . . = ∆nK ,l−1 = 0, T > τ ]
=
Pr[vl−1 < T ≤ vl, K = k, T > v0,∆1,l−1 = . . . = ∆nK ,l−1 = 0|Hl−1 = hl−1, Vl−1 = vl−1]
Pr[∆1,l−1 = . . . = ∆nK ,l−1 = 0, T > v0|Hl−1 = hl−1, Vl−1 = vl−1]
=
Pr[vl−1 < T ≤ vl, K = k, T > v0|Hl−1 = hl−1, Vl−1 = vl−1]
Pr[T > vl−1, T > v0|Hl−1 = hl−1, Vl−1 = vl−1] , since τ ≤ vl−1
=
Pr[vl−1 < T ≤ vl, K = k|Hl−1 = hl−1]
Pr[T > vl−1|Hl−1 = hl−1]
=
Pr[vl−1 < T ≤ vl, K = k|Hl−2 = hl−2, Vl−2 = vl−2,∆1,l−2 = . . . = ∆nK ,l−2 = 0, T > v0]
Pr[T > vl−1|Hl−2 = hl−2, Vl−2 = vl−2,∆1,l−2 = . . . = ∆nK ,l−2 = 0, T > v0]
=
Pr[vl−1 < T ≤ vl, K = k,∆1,l−2 = . . . = ∆nK ,l−2 = 0, T > v0|Hl−2 = hl−2, Vl−2 = vl−2]
Pr[T > vl−1,∆1,l−2 = . . . = ∆nK ,l−2 = 0, T > v0|Hl−2 = hl−2, Vl−2 = vl−2]
=
Pr[vl−1 < T ≤ vl, K = k|Hl−2 = hl−2]
Pr[T > vl−1|Hl−2 = hl−2]
= . . . =
Pr[vl−1 < T ≤ vl, K = k]
Pr[T > vl−1]
=
Pr[vl−1 < T ≤ vl, K = k]
Pr[T > vl−1]
=
Fk(vl; Θk)− Fk(vl−1; Θk)
1−∑nKk=1 Fk(vl−1; Θk)
and
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Pr[∆1l = . . . = ∆nKl = 0, T > v0|Hl = hl, Vl = vl] = 1−
nK∑
k=1
Pr[∆kl = 1, T > v0|Hl = hl, Vl = vl]
= 1−
nK∑
k=1
Fk(vl; Θk)− Fk(vl−1; Θk)
1−∑nKk=1 Fk(vl−1; Θk)
= 1−
nK∑
k=1
Fk(vl; Θk)− Fk(vl−1; Θk)
1− F (vl−1; Θk)
= 1− F (vl)− F (vl−1; Θk)
1− F (vl−1; Θk) =
1− F (vl; Θk)
1− F (vl−1; Θk) .
For ∆kM = 1,
1
Pr[T > τ ]
{
m−1∏
l=1
1− F (vl; Θk)
1− F (vl−1; Θk)
}
Fk(vm; Θk)− Fk(vm−1; Θk)
1− F (vm−1; Θk)
=
Fk(vm; Θk)− Fk(vm−1; Θk)
Pr[T > v0]
=
Fk(vm; Θk)− Fk(vm−1; Θk)
1− F (v0; Θk) ,
and for ∆1M = ∆2M = . . . = ∆nKM = 0,
1
Pr[T > v0]
m∏
l=1
Pr[Vl = vl|Hl = hl]Pr[∆1M = . . . = ∆nKM = 0, T > v0|Hl = hl, Vl = vl]
=
1
Pr[T > v0]
m∏
l=1
Pr[Vl = vl|Hl = hl]Pr[T > vm]
∼ Pr[T > vm]
Pr[T > v0]
=
1− F (vm; Θk)
1− F (v0; Θk) .
Therefore, the log likelihood is expressed by
logL(Θ) =
n∑
i=1
log l(Yi; Θ),
where
l(Yi; Θ) =
nK∏
k=1
M∏
l=1
{
Fk(vl; Θk)− Fk(vl−1; Θk)
1− F (v0; Θk)
}∆kl {1− F (vm; Θk)
1− F (v0; Θk)
}∆M+1
.
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Appendix B: Asymptotic Variance of Fk(t; Θˆk) for Gompertz Model
The approximate variance of Fk(t; Θˆk) = 1− exp[βˆk{1− exp(αˆkt)}/αˆk] for k = 1, . . . , nK
has the following form
v̂ar{Fk(t; Θˆk)} =
(
∂Fk(t; Θk)
∂Θk
)
ΣˆΘˆ
(
∂Fk(t; Θk)
∂Θk
)′∣∣∣∣
Θ=Θˆ
,
where ΣˆΘˆ is the inverse of the following observed Fisher information matrix
−

∂2 logL(Θ)
∂α21
∂2 logL(Θ)
∂α1∂β1
∂2 logL(Θ)
∂α1∂α2
. . . ∂
2 logL(Θ)
∂α1∂βnK
∂2 logL(Θ)
∂α1∂β1
∂2 logL(Θ)
∂β21
∂2 logL(Θ)
∂α2∂β1
. . . ∂
2 logL(Θ)
∂β1∂βnK
...
...
...
...
...
∂2 logL(Θ)
∂α1∂βnK
∂2 logL(Θ)
∂β1∂βnK
∂2 logL(Θ)
∂α2∂βnK
. . . ∂
2 logL(Θ)
∂β2nK

.
By letting Dkl(Θk) = {Fk(Vl; Θk)− Fk(Vl−1; Θk)}, we have
∂ log l(Yi; Θ)
∂αk
=
M∑
l=1
∆kl
[
1
Dkl(Θk)
∂Dkl(Θk)
∂αk
+
1
1− F (τ ; Θk)
∂Fk(τ ; Θk)
∂αk
]
+∆M+1
[ −1
1− F (vM ; Θk)
∂Fk(vM ; Θk)
∂αk
+
1
1− F (τ ; Θk)
∂Fk(τ ; Θk)
∂αk
]
,
∂2 log l(Yi; Θ)
∂α2k
=
M∑
l=1
∆kl
[
1
D2kl(Θk)
{
∂2Dkl(Θk)
∂α2k
Dkl(Θk)−
(
∂Dkl(Θk)
∂αk
)2}
+
1
{1− F (τ ; Θk)}2
{
∂2Fk(τ ; Θk)
∂α2k
{1− F (τ ; Θk)}+
(
∂Fk(τ ; Θk)
∂αk
)2}]
+∆M+1
[
−1
{1− F (vM ; Θk)}2
{
∂2Fk(vM ; Θk)
∂α2k
{1− F (vM ; Θk)}+
(
∂Fk(vM ; Θk)
∂αk
)2}
+
1
{1− F (τ ; Θk)}2
{
∂2Fk(τ ; Θk)
∂α2k
{1− F (τ ; Θk)}+
(
∂Fk(τ ; Θk)
∂αk
)2}]
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and
∂2 log l(Yi; Θ)
∂αk∂βk
=
M∑
l=1
∆kl
[
1
D2kl(Θk)
{
∂2Dkl(Θk)
∂αk∂βk
Dkl(Θk)− ∂Dkl(Θk)
∂αk
∂Dkl(Θk)
∂βk
}
+
1
{1− F (τ ; Θk)}2
{
∂2Fk(τ ; Θk)
∂αk∂βk
{1− F (τ ; Θk)}+ ∂Fk(τ ; Θk)
∂αk
∂Fk(τ ; Θk)
∂βk
}]
+∆M+1
[ −1
{1− F (vM ; Θk)}2
{
∂2Fk(vM ; Θk)
∂αk∂βk
{1− F (vM ; Θk)}+ ∂Fk(vM ; Θk)
∂αk
∂Fk(vM ; Θk)
∂βk
}
+
1
{1− F (τ ; Θk)}2
{
∂2Fk(τ ; Θk)
∂αk∂βk
{1− F (τ ; Θk)}+ ∂Fk(τ ; Θk)
∂αk
∂Fk(τ ; Θk)
∂βk
}]
,
where
∂Fk(t; Θk)
∂αk
= {1− Fk(t; Θk)}{1 + exp(αkt)(αkt− 1)}βk/α2k,
∂Fk(t; Θk)
∂βk
= {1− Fk(t; Θk)}{exp(αkt)− 1}/αk,
∂2Fk(t; Θk)
∂α2k
=
−∂Fk(t; Θk)
∂αk
[
βk
α2k
+
βk
α2k
exp(αkt)(αkt− 1)
]
+{1− Fk(t; Θk)}
[−2βk
α3k
+
{
βkα
−1
k t
2 + 2βkα
−3
k − 2βkα−2k t
}
exp(αkt)
]
,
∂2Fk(t; Θk)
∂β2k
= −{exp(αkt)− 1}2{1− Fk(t; Θk)}/α2k,
∂2Fk(t; Θk)
∂αk∂βk
= −{1− Fk(t; Θk)}{(αkt− 1) exp(αkt) + 1}{(exp(αkt)− 1)βk − αk}/α3k.
The other mixed partial second derivatives are omitted.
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